

Edgar Filing: Zoetis Inc. - Form 10-Q

Zoetis Inc.  
Form 10-Q  
May 02, 2019

false--12-31Q120192019-03-3110-Q0001555280falseLarge Accelerated  
FilerfalseZTS15990000001642000000240000002400000010000000.010.0160000000005018912435018912434795623260.0  
0001555280 2019-01-01 2019-03-31 0001555280 2019-04-26 0001555280 2018-01-01 2018-03-31 0001555280  
2018-12-31 0001555280 2019-03-31 0001555280 2018-03-31 0001555280 us-gAAP:RetainedEarningsMember  
2018-12-31 0001555280 us-gAAP:AdditionalPaidInCapitalMember 2018-03-31 0001555280  
us-gAAP:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001555280 us-gAAP:NoncontrollingInterestMember  
2019-01-01 2019-03-31 0001555280 us-gAAP:AdditionalPaidInCapitalMember 2019-03-31 0001555280  
us-gAAP:TreasuryStockMember 2018-01-01 2018-03-31 0001555280 us-gAAP:CommonStockMember 2017-12-31  
0001555280 us-gAAP:RetainedEarningsMember 2018-01-01 2018-03-31 0001555280 us-gAAP:TreasuryStockMember  
2017-12-31 0001555280 us-gAAP:CommonStockMember 2018-03-31 0001555280 us-gAAP:TreasuryStockMember  
2018-12-31 0001555280 us-gAAP:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001555280  
us-gAAP:NoncontrollingInterestMember 2017-12-31 0001555280 us-gAAP:TreasuryStockMember 2019-03-31  
0001555280 us-gAAP:CommonStockMember 2019-03-31 0001555280 us-gAAP:TreasuryStockMember 2019-01-01  
2019-03-31 0001555280 us-gAAP:RetainedEarningsMember 2019-03-31 0001555280  
us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001555280  
us-gAAP:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001555280  
us-gAAP:NoncontrollingInterestMember 2018-12-31 0001555280  
us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001555280  
us-gAAP:RetainedEarningsMember 2019-01-01 2019-03-31 0001555280 us-gAAP:CommonStockMember 2018-12-31  
0001555280 us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001555280  
us-gAAP:NoncontrollingInterestMember 2018-03-31 0001555280 us-gAAP:NoncontrollingInterestMember 2019-03-31  
0001555280 us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001555280  
us-gAAP:RetainedEarningsMember 2018-03-31 0001555280 us-gAAP:AdditionalPaidInCapitalMember 2018-12-31  
0001555280 us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001555280  
us-gAAP:AdditionalPaidInCapitalMember 2017-12-31 0001555280 2017-12-31 0001555280  
us-gAAP:RetainedEarningsMember 2017-12-31 0001555280  
us-gAAP:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001555280 us-gAAP:TreasuryStockMember  
2018-03-31 0001555280 us-gAAP:ProductMember 2019-03-31 0001555280 zts:LivestockMember  
zts:UnitedStatesSegmentMember 2019-01-01 2019-03-31 0001555280  
zts:ContractManufacturingandHumanHealthDiagnosticsMember 2019-01-01 2019-03-31 0001555280  
zts:LivestockMember zts:InternationalSegmentMember 2018-01-01 2018-03-31 0001555280  
zts:CompanionAnimalMember zts:InternationalSegmentMember 2019-01-01 2019-03-31 0001555280  
zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2019-01-01 2019-03-31 0001555280  
zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2018-01-01 2018-03-31 0001555280  
zts:LivestockMember zts:InternationalSegmentMember 2019-01-01 2019-03-31 0001555280 zts:LivestockMember  
zts:UnitedStatesSegmentMember 2018-01-01 2018-03-31 0001555280  
zts:ContractManufacturingandHumanHealthDiagnosticsMember 2018-01-01 2018-03-31 0001555280  
zts:CompanionAnimalMember zts:InternationalSegmentMember 2018-01-01 2018-03-31 0001555280  
us-gAAP:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2018-01-01 2018-03-31 0001555280  
us-gAAP:OperatingSegmentsMember zts:InternationalSegmentMember 2019-01-01 2019-03-31 0001555280  
us-gAAP:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2019-01-01 2019-03-31 0001555280  
us-gAAP:OperatingSegmentsMember zts:InternationalSegmentMember 2018-01-01 2018-03-31 0001555280  
zts:LivestockMember 2018-01-01 2018-03-31 0001555280 zts:CattleMember 2018-01-01 2018-03-31 0001555280  
zts:CompanionAnimalMember 2019-01-01 2019-03-31 0001555280 zts:PoultryMember 2018-01-01 2018-03-31  
0001555280 zts:SwineMember 2019-01-01 2019-03-31 0001555280 zts:DogsAndCatsMember 2019-01-01  
2019-03-31 0001555280 us-gAAP:ManufacturedProductOtherMember 2019-01-01 2019-03-31 0001555280  
zts:CompanionAnimalMember 2018-01-01 2018-03-31 0001555280 zts:FishMember 2018-01-01 2018-03-31  
0001555280 zts:LivestockMember 2019-01-01 2019-03-31 0001555280 zts:DogsAndCatsMember 2018-01-01

Edgar Filing: Zoetis Inc. - Form 10-Q

2018-03-31 0001555280 zts:HorsesMember 2019-01-01 2019-03-31 0001555280 zts:HorsesMember 2018-01-01  
2018-03-31 0001555280 us-gaap:ManufacturedProductOtherMember 2018-01-01 2018-03-31 0001555280  
zts:FishMember 2019-01-01 2019-03-31 0001555280 zts:PoultryMember 2019-01-01 2019-03-31 0001555280  
zts:SwineMember 2018-01-01 2018-03-31 0001555280 zts:CattleMember 2019-01-01 2019-03-31 0001555280  
zts:VaccinesMember 2019-01-01 2019-03-31 0001555280 zts:MedicatedFeedAdditivesMember 2019-01-01  
2019-03-31 0001555280 zts:TotalProductsandServicesMember 2018-01-01 2018-03-31 0001555280  
zts:ParasitocidesMember 2018-01-01 2018-03-31 0001555280 zts:OtherPharmaceuticalsMember 2019-01-01  
2019-03-31 0001555280 zts:AnimalHealthDiagnosticsMember 2019-01-01 2019-03-31 0001555280  
zts:VaccinesMember 2018-01-01 2018-03-31 0001555280 zts:TotalProductsandServicesMember 2019-01-01  
2019-03-31 0001555280 zts:AntiInfectiveProductsMember 2018-01-01 2018-03-31 0001555280  
zts:MedicatedFeedAdditivesMember 2018-01-01 2018-03-31 0001555280 zts:OtherNonPharmaceuticalsMember  
2018-01-01 2018-03-31 0001555280 zts:OtherPharmaceuticalsMember 2018-01-01 2018-03-31 0001555280  
zts:ParasitocidesMember 2019-01-01 2019-03-31 0001555280 zts:OtherNonPharmaceuticalsMember 2019-01-01  
2019-03-31 0001555280 zts:AntiInfectiveProductsMember 2019-01-01 2019-03-31 0001555280  
zts:AnimalHealthDiagnosticsMember 2018-01-01 2018-03-31 0001555280 country:US 2018-01-01 2018-03-31  
0001555280 zts:TotalGeographicalAreaMember 2019-01-01 2019-03-31 0001555280 country:FR 2019-01-01  
2019-03-31 0001555280 country:MX 2019-01-01 2019-03-31 0001555280 country:CN 2018-01-01 2018-03-31  
0001555280 country:BR 2019-01-01 2019-03-31 0001555280 country:IT 2019-01-01 2019-03-31 0001555280  
country:JP 2018-01-01 2018-03-31 0001555280 country:IT 2018-01-01 2018-03-31 0001555280 country:BR  
2018-01-01 2018-03-31 0001555280 country:MX 2018-01-01 2018-03-31 0001555280 country:AU 2018-01-01  
2018-03-31 0001555280 country:CN 2019-01-01 2019-03-31 0001555280 country:DE 2019-01-01 2019-03-31  
0001555280 country:DE 2018-01-01 2018-03-31 0001555280 country:ES 2018-01-01 2018-03-31 0001555280  
country:AU 2019-01-01 2019-03-31 0001555280 country:ES 2019-01-01 2019-03-31 0001555280 country:FR  
2018-01-01 2018-03-31 0001555280 zts:OtherEmergingMarketsMember 2019-01-01 2019-03-31 0001555280  
country:CA 2019-01-01 2019-03-31 0001555280 zts:TotalGeographicalAreaMember 2018-01-01 2018-03-31  
0001555280 country:GB 2019-01-01 2019-03-31 0001555280 zts:OtherDevelopedMarketsMember 2019-01-01  
2019-03-31 0001555280 country:CA 2018-01-01 2018-03-31 0001555280 zts:OtherEmergingMarketsMember  
2018-01-01 2018-03-31 0001555280 zts:OtherDevelopedMarketsMember 2018-01-01 2018-03-31 0001555280  
country:US 2019-01-01 2019-03-31 0001555280 country:GB 2018-01-01 2018-03-31 0001555280 country:JP  
2019-01-01 2019-03-31 0001555280 zts:AbaxisIncMember 2018-07-31 0001555280 zts:AbaxisIncMember  
2019-01-01 2019-03-31 0001555280 zts:AbaxisIncMember zts:MeasurementperiodadjustmentMember 2018-07-31  
0001555280 zts:AbaxisIncMember 2018-07-31 2018-07-31 0001555280 zts:AbaxisIncMember  
zts:BusinessCombinationPreMergerServiceMember 2018-07-31 0001555280  
us-gaap:OtherNoncurrentLiabilitiesMember 2019-03-31 0001555280 us-gaap:OtherCurrentLiabilitiesMember  
2019-03-31 0001555280 zts:ManufacturingResearchCorporateMember 2019-01-01 2019-03-31 0001555280  
us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-31 0001555280 us-gaap:OtherCurrentLiabilitiesMember  
2018-12-31 0001555280 zts:ManufacturingResearchCorporateMember 2018-01-01 2018-03-31 0001555280  
zts:DirectCostMember 2018-01-01 2018-03-31 0001555280 us-gaap:EmployeeSeveranceMember 2018-01-01  
2018-03-31 0001555280 zts:DirectCostMember 2019-01-01 2019-03-31 0001555280  
us-gaap:EmployeeSeveranceMember 2019-01-01 2019-03-31 0001555280 zts:NoncurrentDeferredTaxAssetsMember  
2018-12-31 0001555280 zts:NonU.S.StatutoryTaxRatesMember 2018-01-01 2018-03-31 0001555280  
zts:OtherTaxesPayableMember 2019-03-31 0001555280 zts:SharebasedPaymentsMember 2019-01-01 2019-03-31  
0001555280 zts:SharebasedPaymentsMember 2018-01-01 2018-03-31 0001555280  
zts:NoncurrentDeferredTaxAssetsMember 2019-03-31 0001555280 zts:NonU.S.StatutoryTaxRatesMember  
2019-01-01 2019-03-31 0001555280 zts:OtherTaxesPayableMember 2018-12-31 0001555280  
us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01  
2018-03-31 0001555280 us-gaap:CrossCurrencyInterestRateContractMember  
us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0001555280  
zts:SeniorNotes3.000Due2027Member us-gaap:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes3.000Due2027Member us-gaap:SeniorNotesMember 2019-03-31 0001555280

Edgar Filing: Zoetis Inc. - Form 10-Q

zts:SeniorNotesFloatingDue2021Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.950Due2047Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.900Due2028Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes4.450Due2048Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.450Due2020Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotesFloatingDue2021Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes3.250Due2021Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.900Due2028Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotesDue2043Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes4.450Due2048Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes3.250Due2021Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotesDue2023Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotesDue2043Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes4.500Due2025Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.950Due2047Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes3.450Due2020Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotes4.500Due2025Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
us-gAAP:CorporateDebtSecuritiesMember 2018-12-31 0001555280 us-gAAP:CorporateDebtSecuritiesMember  
2019-03-31 0001555280 us-gAAP:USTreasuryAndGovernmentMember 2019-03-31 0001555280  
us-gAAP:USTreasuryAndGovernmentMember 2018-12-31 0001555280 zts:SeniorNotes3.250Due2021Member  
us-gAAP:SeniorNotesMember 2018-08-20 0001555280 zts:SeniorNotes3.900Due2028Member  
us-gAAP:SeniorNotesMember 2018-08-20 0001555280 us-gAAP:CommercialPaperMember 2013-02-28 0001555280  
us-gAAP:CrossCurrencyInterestRateContractMember 2019-03-31 0001555280 zts:SeniorNotes4.450Due2048Member  
us-gAAP:SeniorNotesMember 2018-08-20 0001555280 zts:SeniorNotesDue2018Member us-gAAP:SeniorNotesMember  
2013-01-28 0001555280 us-gAAP:InterestRateSwapMember us-gAAP:DesignatedAsHedgingInstrumentMember  
2019-03-31 0001555280 us-gAAP:SeniorNotesMember 2018-08-20 0001555280 us-gAAP:SeniorNotesMember  
2013-01-28 0001555280 us-gAAP:RevolvingCreditFacilityMember 2019-03-31 0001555280  
us-gAAP:FairValueInputsLevel2Member us-gAAP:SeniorNotesMember 2019-03-31 0001555280  
zts:SeniorNotesFloatingDue2021Member us-gAAP:SeniorNotesMember 2018-08-20 0001555280  
us-gAAP:ForeignExchangeForwardMember us-gAAP:NondesignatedMember 2018-12-31 0001555280  
zts:SeniorNotesDue2018Member us-gAAP:SeniorNotesMember 2017-10-31 0001555280  
us-gAAP:CrossCurrencyInterestRateContractMember 2018-12-31 0001555280 us-gAAP:SeniorNotesMember  
2015-11-13 0001555280 zts:SeniorNotes3.000Due2027Member us-gAAP:SeniorNotesMember 2017-09-12  
0001555280 zts:OperationalEfficiencyMember 2019-01-01 2019-03-31 0001555280  
us-gAAP:FairValueInputsLevel2Member us-gAAP:SeniorNotesMember 2018-12-31 0001555280  
zts:SeniorNotes3.950Due2047Member us-gAAP:SeniorNotesMember 2017-09-12 0001555280  
us-gAAP:SeniorNotesMember 2017-09-12 0001555280 us-gAAP:ForeignExchangeForwardMember  
us-gAAP:NondesignatedMember 2019-03-31 0001555280 us-gAAP:ForeignExchangeForwardMember  
us-gAAP:NondesignatedMember 2018-01-01 2018-03-31 0001555280 us-gAAP:ForeignExchangeForwardMember  
us-gAAP:NondesignatedMember 2019-01-01 2019-03-31 0001555280 us-gAAP:OtherCurrentAssetsMember  
us-gAAP:CrossCurrencyInterestRateContractMember us-gAAP:DesignatedAsHedgingInstrumentMember 2018-12-31  
0001555280 us-gAAP:CrossCurrencyInterestRateContractMember us-gAAP:DesignatedAsHedgingInstrumentMember  
2018-12-31 0001555280 us-gAAP:OtherNoncurrentAssetsMember  
us-gAAP:CrossCurrencyInterestRateContractMember us-gAAP:DesignatedAsHedgingInstrumentMember 2019-03-31  
0001555280 us-gAAP:OtherCurrentAssetsMember us-gAAP:CrossCurrencyInterestRateContractMember  
us-gAAP:DesignatedAsHedgingInstrumentMember 2019-03-31 0001555280 us-gAAP:OtherCurrentAssetsMember  
us-gAAP:ForeignExchangeForwardMember us-gAAP:NondesignatedMember 2019-03-31 0001555280  
us-gAAP:OtherCurrentLiabilitiesMember us-gAAP:ForeignExchangeForwardMember us-gAAP:NondesignatedMember  
2018-12-31 0001555280 us-gAAP:OtherCurrentLiabilitiesMember us-gAAP:ForeignExchangeForwardMember  
us-gAAP:NondesignatedMember 2019-03-31 0001555280 us-gAAP:CrossCurrencyInterestRateContractMember  
us-gAAP:DesignatedAsHedgingInstrumentMember 2019-03-31 0001555280 us-gAAP:OtherCurrentAssetsMember

Edgar Filing: Zoetis Inc. - Form 10-Q

us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001555280  
us-gaap:RevolvingCreditFacilityMember 2018-07-27 0001555280 zts:SeniorNotes3.450Due2020Member  
us-gaap:SeniorNotesMember 2015-11-13 0001555280 zts:SeniorNotesDue2023Member us-gaap:SeniorNotesMember  
2013-01-28 0001555280 zts:SeniorNotes4.500Due2025Member us-gaap:SeniorNotesMember 2015-11-13  
0001555280 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31  
0001555280 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember  
2019-01-01 2019-03-31 0001555280 zts:SeniorNotesDue2043Member us-gaap:SeniorNotesMember 2013-01-28  
0001555280 2018-01-01 2018-12-31 0001555280 srt:MinimumMember 2019-03-31 0001555280  
srt:MaximumMember 2019-03-31 0001555280 zts:InternationalMember 2019-01-01 2019-03-31 0001555280  
zts:InternationalMember 2018-12-31 0001555280 zts:InternationalMember 2019-03-31 0001555280 country:US  
2019-03-31 0001555280 country:US 2018-12-31 0001555280 us-gaap:TrademarksAndTradeNamesMember  
2018-12-31 0001555280 zts:BrandsMember 2019-03-31 0001555280 zts:BrandsMember 2018-12-31 0001555280  
us-gaap:TrademarksAndTradeNamesMember 2019-03-31 0001555280 zts:ProductRightsMember 2018-12-31  
0001555280 us-gaap:OtherIntangibleAssetsMember 2019-03-31 0001555280  
us-gaap:DevelopedTechnologyRightsMember 2019-03-31 0001555280  
us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001555280  
us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001555280 us-gaap:OtherIntangibleAssetsMember  
2018-12-31 0001555280 us-gaap:TrademarksAndTradeNamesMember 2019-03-31 0001555280  
us-gaap:InProcessResearchAndDevelopmentMember 2019-03-31 0001555280 zts:BrandsMember 2019-03-31  
0001555280 us-gaap:TrademarksAndTradeNamesMember 2018-12-31 0001555280 zts:BrandsMember 2018-12-31  
0001555280 zts:ProductRightsMember 2019-03-31 0001555280 us-gaap:TrademarksAndTradeNamesMember  
2019-01-01 2019-03-31 0001555280 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-03-31  
0001555280 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-03-31 0001555280  
us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001555280 us-gaap:EmployeeStockOptionMember  
2018-01-01 2018-03-31 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001555280  
us-gaap:PerformanceSharesMember 2018-01-01 2018-03-31 0001555280 us-gaap:RestrictedStockUnitsRSUMember  
2018-01-01 2018-03-31 0001555280 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001555280  
srt:MaximumMember us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001555280  
srt:MinimumMember us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001555280  
zts:PeerCompaniesMember us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001555280  
us-gaap:StockCompensationPlanMember 2018-01-01 2018-03-31 0001555280 zts:ShareRepurchaseProgramMember  
2019-01-01 2019-03-31 0001555280 us-gaap:StockCompensationPlanMember 2019-01-01 2019-03-31 0001555280  
zts:ShareRepurchaseProgramMember 2018-01-01 2018-03-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31  
0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001555280  
us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001555280  
us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0001555280  
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001555280  
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001555280  
us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31  
0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0001555280  
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001555280  
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0001555280  
us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0001555280  
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0001555280  
us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0001555280  
us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001555280

us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001555280  
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001555280  
us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001555280  
zts:December2016ShareRepurchaseProgramMember 2017-12-31 0001555280  
zts:December2018ShareRepurchaseProgramMember 2018-12-31 0001555280 zts:LascadoilMember 2019-01-01  
2019-03-31 0001555280 zts:LascadoilMember 2014-08-01 2014-08-31 0001555280 zts:LascadoilMember  
2015-06-03 2015-06-03 0001555280 zts:EuropeanCommissionMember 2013-06-19 0001555280  
zts:UlianopolisBrazilMember 2012-02-29 0001555280 zts:LascadoilMember 2016-05-16 2016-05-16 0001555280  
zts:UlianopolisBrazilMember 2012-04-01 2012-04-30 0001555280 us-gaap:OperatingSegmentsMember 2019-01-01  
2019-03-31 0001555280 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-03-31 0001555280  
us-gaap:AcquisitionRelatedCostsMember 2019-01-01 2019-03-31 0001555280 us-gaap:OperatingSegmentsMember  
2018-01-01 2018-03-31 0001555280 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0001555280  
us-gaap:AcquisitionRelatedCostsMember 2018-01-01 2018-03-31 0001555280 us-gaap:AllOtherSegmentsMember  
2018-01-01 2018-03-31 0001555280 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0001555280  
us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001555280 us-gaap:CorporateNonSegmentMember  
2018-01-01 2018-03-31 0001555280 us-gaap:OperatingSegmentsMember currency:EUR  
zts:InternationalSegmentMember 2018-01-01 2018-03-31 0001555280 us-gaap:MaterialReconcilingItemsMember  
zts:ZoetisInitiativesMember 2019-01-01 2019-03-31 0001555280 us-gaap:OperatingSegmentsMember currency:EUR  
zts:InternationalSegmentMember 2019-01-01 2019-03-31 zts:species xbrli:shares iso4217:USD xbrli:pure zts:swap  
iso4217:CHF iso4217:USD xbrli:shares zts:country zts:region zts:category iso4217:EUR zts:product\_category  
zts:customer zts:count zts:defendant zts:segment zts:animal zts:producer

[Table of Contents](#)

---

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

or

TRANSITION REPORT PURSUANT TO SECTION 13  
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-35797

## Zoetis Inc.

(Exact name of registrant as specified in its charter)

Delaware 46-0696167  
(State or other jurisdiction of (I.R.S. Employer Identification No.)  
incorporation or organization)

10 Sylvan Way, Parsippany, New Jersey 07054  
(Address of principal executive offices) (Zip Code)

(973) 822-7000  
(Registrant's telephone number, including area code)

Edgar Filing: Zoetis Inc. - Form 10-Q

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  
 Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of

Edgar Filing: Zoetis Inc. - Form 10-Q

“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	ZTS	New York Stock Exchange

At April 26, 2019, there were 478,656,189 shares of common stock outstanding.

Table of Contents

**TABLE OF CONTENTS**

	<u>Page</u>
<b><u>PART I — FINANCIAL INFORMATION</u></b>	<b><u>1</u></b>
Item 1. <u>Financial Statements</u>	<u>1</u>
Condensed Consolidated Statements of Income (Unaudited)	<u>1</u>
Condensed Consolidated Statements of Comprehensive Income (Unaudited)	<u>2</u>
Condensed Consolidated Balance Sheets (Unaudited)	<u>3</u>
Condensed Consolidated Statements of Equity (Unaudited)	<u>4</u>
Condensed Consolidated Statements of Cash Flows (Unaudited)	<u>5</u>
Notes to Condensed Consolidated Financial Statements (Unaudited)	<u>6</u>
Review Report of Independent Registered Public Accounting Firm	<u>25</u>
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>26</u>
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>43</u>
Item 4. <u>Controls and Procedures</u>	<u>43</u>
<b><u>PART II — OTHER INFORMATION</u></b>	<b><u>44</u></b>
Item 1. <u>Legal Proceedings</u>	<u>44</u>
Item 1A. <u>Risk Factors</u>	<u>44</u>
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>44</u>
Item 3. <u>Defaults Upon Senior Securities</u>	<u>44</u>
Item 4. <u>Mine Safety Disclosures</u>	<u>44</u>
Item 5. <u>Other Information</u>	<u>44</u>
Item 6. <u>Exhibits</u>	<u>44</u>
<b><u>SIGNATURES</u></b>	<b><u>45</u></b>

---



Table of Contents**PART I – FINANCIAL INFORMATION****Item 1. Financial Statements****ZOETIS INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME  
(UNAUDITED)**

	Three Months Ended <b>March 31,</b>	
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	<b>2019</b>	2018
Revenue	<b>\$1,455</b>	\$1,366
Costs and expenses:		
Cost of sales	<b>518</b>	447
Selling, general and administrative expenses	<b>369</b>	338
Research and development expenses	<b>102</b>	97
Amortization of intangible assets	<b>38</b>	23
Restructuring charges and certain acquisition-related costs	<b>5</b>	2
Interest expense, net of capitalized interest	<b>56</b>	47
Other (income)/deductions—net	<b>(14)</b>	(5)
Income before provision for taxes on income	<b>381</b>	417
Provision for taxes on income	<b>69</b>	67
Net income before allocation to noncontrolling interests	<b>312</b>	350
Less: Net loss attributable to noncontrolling interests	<b>—</b>	(2)
Net income attributable to Zoetis Inc.	<b>\$312</b>	\$352
Earnings per share attributable to Zoetis Inc. stockholders:		
Basic	<b>\$0.65</b>	\$0.72
Diluted	<b>\$0.65</b>	\$0.72
Weighted-average common shares outstanding:		
Basic	<b>479.6</b>	485.9
Diluted	<b>483.1</b>	489.8
Dividends declared per common share	<b>\$0.164</b>	\$0.126

See notes to condensed consolidated financial statements.

1 |

Table of Contents

**ZOETIS INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**(UNAUDITED)**

	Three Months Ended <b>March 31,</b>	
(MILLIONS OF DOLLARS)	<b>2019</b>	2018
Net income before allocation to noncontrolling interests	<b>\$312</b>	\$350
Other comprehensive income, net of taxes and reclassification adjustments:		
Foreign currency translation adjustments, net	<b>31</b>	77
Total other comprehensive income, net of tax	<b>31</b>	77
Comprehensive income before allocation to noncontrolling interests	<b>343</b>	427
Less: Comprehensive loss attributable to noncontrolling interests	—	(1 )
Comprehensive income attributable to Zoetis Inc.	<b>\$343</b>	\$428

See notes to condensed consolidated financial statements.

2 |

---

Table of Contents**ZOETIS INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS**

	<b>March 31, 2019</b>	December 31, 2018
	(Unaudited)	
(MILLIONS OF DOLLARS, EXCEPT SHARE AND PER SHARE DATA)		
<u>Assets</u>		
Cash and cash equivalents <sup>(a)</sup>	<b>\$ 1,728</b>	\$ 1,602
Short term investments	<b>65</b>	99
Accounts receivable, less allowance for doubtful accounts of \$24 in 2019 and \$24 in 2018	<b>970</b>	1,036
Inventories	<b>1,361</b>	1,391
Other current assets	<b>255</b>	271
Total current assets	<b>4,379</b>	4,399
Property, plant and equipment, less accumulated depreciation of \$1,642 in 2019 and \$1,599 in 2018	<b>1,683</b>	1,658
Operating lease right of use assets	<b>158</b>	—
Goodwill	<b>2,522</b>	2,519
Identifiable intangible assets, less accumulated amortization	<b>1,989</b>	2,046
Noncurrent deferred tax assets	<b>65</b>	61
Other noncurrent assets	<b>87</b>	94
Total assets	<b>\$ 10,883</b>	\$ 10,777
<u>Liabilities and Equity</u>		
Short-term borrowings	<b>\$ —</b>	\$ 9
Accounts payable	<b>235</b>	313
Dividends payable	<b>79</b>	79
Accrued expenses	<b>448</b>	487
Accrued compensation and related items	<b>200</b>	266
Income taxes payable	<b>65</b>	35
Other current liabilities	<b>55</b>	34
Total current liabilities	<b>1,082</b>	1,223
Long-term debt, net of discount and issuance costs	<b>6,444</b>	6,443
Noncurrent deferred tax liabilities	<b>464</b>	474
Operating lease liabilities	<b>134</b>	—
Other taxes payable	<b>261</b>	265
Other noncurrent liabilities	<b>181</b>	187
Total liabilities	<b>8,566</b>	8,592
Commitments and contingencies (Note 16)		
Stockholders' equity:		
Preferred stock, \$0.01 par value: 1,000,000,000 authorized, none issued	—	—
Common stock, \$0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 479,026,001 and 479,562,326 shares outstanding at March 31, 2019, and December 31, 2018, respectively	<b>5</b>	5
Treasury stock, at cost, 22,865,242 and 22,328,917 shares of common stock at March 31, 2019, and December 31, 2018, respectively	<b>(1,593)</b>	(1,487)
Additional paid-in capital	<b>1,008</b>	1,026
Retained earnings	<b>3,495</b>	3,270
Accumulated other comprehensive loss	<b>(598)</b>	(629)
Total equity	<b>2,317</b>	2,185
Total liabilities and equity	<b>\$ 10,883</b>	\$ 10,777

<sup>(a)</sup> As of March 31, 2019, and December 31, 2018, includes \$3 million and \$5 million, respectively, of restricted cash.

See notes to condensed consolidated financial statements.

3 |

---

Table of Contents
**ZOETIS INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY**  
**(UNAUDITED)**

	Zoetis						
	Common	Treasury	Additional	Retained	Accumulated	Equity	Total
(MILLIONS OF DOLLARS)	Stock <sup>(a)</sup>	Stock <sup>(a)</sup>	Paid-in	Earnings	Other	Attributable	Equity
			Capital	Loss	Comprehensive	to	
					Loss	Noncontrolling	
						Interests	Equity
Balance, December 31, 2017	\$ 5	\$(852 )	\$ 1,013	\$ 2,109	\$ (505 )	\$ 16	\$ 1,786
<b><u>Three months ended March 31, 2018</u></b>							
Net income	—	—	—	352	—	(2 )	350
Other comprehensive income	—	—	—	—	76	1	77
Share-based compensation awards <sup>(b)</sup>	—	37	(24 )	(1 )	—	—	12
Treasury stock acquired <sup>(c)</sup>	—	(190 )	—	—	—	—	(190 )
Employee benefit plan contribution from Pfizer Inc. <sup>(d)</sup>	—	—	1	—	—	—	1
Dividends declared	—	—	—	(61 )	—	—	(61 )
Balance, March 31, 2018	\$ 5	\$(1,005 )	\$ 990	\$ 2,399	\$ (429 )	\$ 15	\$ 1,975
Balance, December 31, 2018	\$ 5	\$(1,487 )	\$ 1,026	\$ 3,270	\$ (629 )	\$ —	\$ 2,185
<b><u>Three months ended March 31, 2019</u></b>							
Net income/(loss)	—	—	—	312	—	—	312
Other comprehensive loss	—	—	—	—	31	—	31
Share-based compensation awards <sup>(b)</sup>	—	44	(19 )	(8 )	—	—	17
Treasury stock acquired <sup>(c)</sup>	—	(150 )	—	—	—	—	(150 )
Employee benefit plan contribution from Pfizer Inc. <sup>(d)</sup>	—	—	1	—	—	—	1
Dividends declared	—	—	—	(79 )	—	—	(79 )
Balance, March 31, 2019	\$ 5	\$(1,593 )	\$ 1,008	\$ 3,495	\$ (598 )	\$ —	\$ 2,317

As of March 31, 2019, and March 31, 2018, there were 479,026,001 and 484,724,245 outstanding shares of common stock, respectively, and 22,865,242 and <sup>(a)</sup> 17,166,998 shares of treasury stock, respectively. Treasury stock is recognized at the cost to reacquire the shares. For additional information, see *Note 14. Stockholders' Equity*.

Includes the issuance of shares of Zoetis Inc. common stock and the reissuance of treasury stock in connection with the vesting of employee share-based awards.

<sup>(b)</sup> Treasury stock also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements.

<sup>(c)</sup> Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see *Note 14. Stockholders' Equity*.

<sup>(d)</sup> Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.

See notes to condensed consolidated financial statements.

Table of Contents

**ZOETIS INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**

(MILLIONS OF DOLLARS)	Three Months Ended <b>March 31,</b>	
	<b>2019</b>	2018
<u>Operating Activities</u>		
Net income before allocation to noncontrolling interests	<b>\$312</b>	\$350
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:		
Depreciation and amortization expense	<b>98</b>	60
Share-based compensation expense	<b>18</b>	11
Asset write-offs and asset impairments	<b>1</b>	2
Provision for losses on inventory	<b>14</b>	16
Deferred taxes <sup>(a)</sup>	<b>(16)</b>	(141)
Employee benefit plan contribution from Pfizer Inc.	<b>1</b>	1
Other non-cash adjustments	<b>—</b>	3
Other changes in assets and liabilities, net of acquisitions and divestitures		
Accounts receivable	<b>75</b>	60
Inventories	<b>17</b>	(33)
Other assets	<b>24</b>	(2)
Accounts payable	<b>(79)</b>	(46)
Other liabilities	<b>(103)</b>	(55)
Other tax accounts, net <sup>(a)</sup>	<b>27</b>	163
Net cash provided by operating activities	<b>389</b>	389
<u>Investing Activities</u>		
Purchases of property, plant and equipment	<b>(63)</b>	(53)
Proceeds from maturities and redemptions of investments	<b>36</b>	—
Net proceeds from sales of assets	<b>—</b>	8
Other investing activities	<b>4</b>	—
Net cash used in investing activities	<b>(23)</b>	(45)
<u>Financing Activities</u>		
Decrease in short-term borrowings, net	<b>(9)</b>	—
Payment of contingent consideration related to previously acquired assets	<b>(8)</b>	(12)
Share-based compensation-related proceeds, net of taxes paid on withholding shares	<b>3</b>	2
Purchases of treasury stock	<b>(150)</b>	(190)
Cash dividends paid	<b>(79)</b>	(62)
Net cash used in financing activities	<b>(243)</b>	(262)
Effect of exchange-rate changes on cash and cash equivalents	<b>3</b>	8
Net increase in cash and cash equivalents	<b>126</b>	90
Cash and cash equivalents at beginning of period	<b>1,602</b>	1,564
Cash and cash equivalents at end of period	<b>\$1,728</b>	\$1,654
<u>Supplemental cash flow information</u>		
Cash paid during the period for:		
Income taxes	<b>\$29</b>	\$42
Interest, net of capitalized interest	<b>96</b>	70
Non-cash transactions:		
Capital expenditures	<b>5</b>	1

Edgar Filing: Zoetis Inc. - Form 10-Q

Dividends declared, not paid

79 61

- (a) For 2018, reflects the reclassification of the one-time mandatory deemed repatriation tax from *Noncurrent deferred tax liabilities* to *Income taxes payable* and *Other taxes payable* to properly reflect the liability, which became a fixed obligation in 2018 payable over eight years.

See notes to condensed consolidated financial statements.

5 |

---

Table of Contents

**ZOETIS INC. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(UNAUDITED)**

**1. Organization**

Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. We organize and operate our business in two geographic regions: the United States (U.S.) and International.

We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within six major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives, animal health diagnostics and other pharmaceuticals.

**2. Basis of Presentation**

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the United States are as of and for the three-month periods ended February 28, 2019, and February 28, 2018.

Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2018 Annual Report on Form 10-K.

**3. Accounting Standards****Recently Adopted Accounting Standards**

In February 2018, the FASB issued an accounting standards update which permits companies to reclassify from accumulated other comprehensive income to retained earnings stranded tax effects resulting from the new federal corporate income tax rate. In the period of adoption, a company may choose to either apply the amendments retrospectively to each period in which the effect of the change in federal income tax rate is recognized or to apply the amendments in that reporting period. We adopted this guidance as of January 1, 2019, the required effective date. The company has elected to not reclassify the stranded income tax effects from accumulated other comprehensive income to retained earnings as the amount is insignificant.

In February 2016, the FASB issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right of use asset. Leases will be classified as financing or operating which will drive the expense recognition pattern. For lessees, the income statement presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. Companies may elect to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We adopted this guidance as of January 1, 2019, the required effective date, using the effective date transition method. As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening retained earnings was not required in conjunction with our adoption. For additional information, see *Note 10. Leases*.

We have elected not to reassess whether expired or existing contracts contain leases, nor did we reassess the classification of existing leases as of the adoption date. We did not use hindsight in our assessment of lease terms as of the effective date.

**Recently Issued Accounting Standards**

In August 2018, the FASB issued an accounting standards update which expands the scope of costs associated with cloud computing arrangements that must be capitalized. Under the new guidance, costs associated with implementing a cloud computing arrangement that is a service contract must be capitalized and expensed over the term of the hosting arrangement. The provisions of the update are effective beginning January 1, 2020 for interim and annual periods with early adoption permitted for any interim period after issuance of the update. We are currently assessing the timing of our adoption as well as the potential impact that the standard will have on our consolidated financial statements.



Table of Contents**4. Revenue****A. Revenue from Product Sales**

We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top selling product lines are distributed across both of our operating segments, leveraging our R&D operations and manufacturing and supply chain network.

Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to a single product in all brands, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both livestock and companion animals across each of our major product categories.

In the third quarter of 2018, the company modified the list of major product categories to include a category for animal health diagnostics, which was previously included within other non-pharmaceutical products. The prior period presentation has been revised to reflect the new product categories.

Our major product categories are:

**vaccines:** biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;

**other pharmaceutical products:** allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products;

**anti-infectives:** products that prevent, kill or slow the growth of bacteria, fungi or protozoa;

**parasiticides:** products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;

**medicated feed additives:** products added to animal feed that provide medicines to livestock; and

- **animal health diagnostics:** portable blood and urine analysis systems and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits and blood glucose monitors.

Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals and agribusiness, as well as products and services in complementary areas, including biodevices and genetic tests.

Our livestock products primarily help prevent or treat diseases and conditions to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive increased demand for improved nutrition, particularly animal protein. Second, population growth leads to increased natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve, there is increased focus on food quality and safety.

Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, receiving increased medical treatment and benefiting from advances in animal health medicines and vaccines.

The following tables present our revenue disaggregated by geographic area, species, and major product category.

Table of ContentsRevenue by geographic area

(MILLIONS OF DOLLARS)	Three Months Ended	
	<b>March 31,</b>	
	<b>2019</b>	2018
United States	<b>\$718</b>	\$634
Australia	<b>48</b>	48
Brazil	<b>60</b>	70
Canada	<b>41</b>	40
China	<b>60</b>	64
France	<b>32</b>	33
Germany	<b>37</b>	38
Italy	<b>28</b>	27
Japan	<b>37</b>	41
Mexico	<b>28</b>	24
Spain	<b>27</b>	25
United Kingdom	<b>57</b>	52
Other developed markets	<b>84</b>	79
Other emerging markets	<b>179</b>	185
	<b>1,436</b>	1,360
Contract manufacturing & human health diagnostics	<b>19</b>	6
<b>Total Revenue</b>	<b>\$1,455</b>	\$1,366

Revenue by major species

(MILLIONS OF DOLLARS)	Three Months Ended	
	<b>March 31,</b>	
	<b>2019</b>	2018
<b>U.S.</b>		
Livestock	<b>\$273</b>	\$292
Companion animal	<b>445</b>	342
	<b>718</b>	634
<b>International</b>		
Livestock	<b>434</b>	478
Companion animal	<b>284</b>	248
	<b>718</b>	726
Contract manufacturing & human health diagnostics	<b>19</b>	6
<b>Total Revenue</b>	<b>\$1,455</b>	\$1,366

Table of ContentsRevenue by species

(MILLIONS OF DOLLARS)	Three Months Ended <b>March 31,</b>	
	<b>2019</b>	2018
<b>Livestock:</b>		
Cattle	<b>\$380</b>	\$416
Swine	<b>149</b>	175
Poultry	<b>139</b>	136
Fish	<b>23</b>	22
Other	<b>16</b>	21
	<b>707</b>	770
<b>Companion Animal:</b>		
Dogs and Cats	<b>688</b>	549
Horses	<b>41</b>	41
	<b>729</b>	590
Contract manufacturing & human health diagnostics	<b>19</b>	6
<b>Total Revenue</b>	<b>\$1,455</b>	\$1,366

Revenue by major product category

(MILLIONS OF DOLLARS)	Three Months Ended <b>March 31,</b>	
	<b>2019</b>	2018
Vaccines	<b>\$358</b>	\$356
Anti-infectives	<b>286</b>	297
Other pharmaceuticals	<b>349</b>	319
Parasiticides	<b>231</b>	191
Medicated feed additives	<b>112</b>	137
Animal health diagnostics	<b>60</b>	11
Other non-pharmaceuticals	<b>40</b>	49
	<b>1,436</b>	1,360
Contract manufacturing & human health diagnostics	<b>19</b>	6
<b>Total Revenue</b>	<b>\$1,455</b>	\$1,366

**B. Revenue from Contracts with Customers**

Contract liabilities reflected within *Other current liabilities* as of December 31, 2018 and December 31, 2017, and subsequently recognized as revenue during the first three months of 2019 and 2018 were approximately \$1 million and \$2 million, respectively. Contract liabilities as of March 31, 2019 and March 31, 2018 were approximately \$10 million and \$4 million, respectively.

Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of March 31, 2019 is not material.

**5. Acquisitions and Divestitures****Acquisition of Abaxis, Inc.**

On July 31, 2018, we completed the acquisition of Abaxis, Inc. (Abaxis), a California corporation and a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services. We acquired all of the outstanding common shares of Abaxis for \$83.00 per share in cash resulting in Abaxis becoming our wholly owned subsidiary. The acquisition enhances our presence in animal health diagnostics.

Edgar Filing: Zoetis Inc. - Form 10-Q

The acquisition date fair value of the consideration transferred was approximately \$1,962 million, which consisted of the following:

9 |

---

Table of Contents

(MILLIONS OF DOLLARS)	<b>Amounts</b>
Cash paid to Abaxis' shareholders <sup>(a)</sup>	<b>\$ 1,898</b>
Cash paid for equity awards attributable to pre-merger services <sup>(b)</sup>	54
Fair value of Zoetis equity awards issued in exchange for outstanding Abaxis equity awards pertaining to pre-merger service <sup>(c)</sup>	10
<b>Total consideration</b>	<b>\$ 1,962</b>

<sup>(a)</sup> Represents cash paid for cancellation and conversion of each outstanding share of Abaxis' common stock at the acquisition date.

<sup>(b)</sup> Represents cash paid for cancellation and settlement of restricted stock awards that fully vested in July 2018 as a result of service or pre-existing change-in-control provisions and termination provisions. Includes certain awards that were settled in cash during the first quarter of 2019.

<sup>(c)</sup> Represents the fair value of replacement awards issued for Abaxis equity awards outstanding immediately before the acquisition and attributable to the service period prior to the acquisition. The previous Abaxis equity awards were converted into the Zoetis equity awards at an exchange ratio based on the closing prices of shares of Zoetis Common Stock and Abaxis Common Stock for ten full trading days before the closing of the acquisition.

The acquisition has been accounted for as a business combination with the assets acquired and liabilities assumed measured at estimated fair values as of the acquisition date, primarily using Level 3 inputs, except for investments in debt securities which were valued using Level 2 inputs.

During the three months ended March 31, 2019, the company recorded additional measurement period adjustments which were made to reflect the facts and circumstances in existence as of the acquisition date. These adjustments include a reduction to *Identifiable intangible assets* of \$1 million, offset by the corresponding increase to goodwill. These measurement period adjustments primarily related to changes in preliminary valuation assumptions, including market participant estimates of cash flows, as well as other initial estimates. The fair values in the table below, which presents the preliminary fair values allocated to Abaxis' assets and liabilities as of the acquisition date, have been updated to reflect these measurement period adjustments.

(MILLIONS OF DOLLARS)	<b>Amounts</b>
Cash and cash equivalents	\$ 64
Short term investments <sup>(a)</sup>	107
Accounts receivable <sup>(b)</sup>	30
Inventories <sup>(c)</sup>	79
Other current assets	6
Property, plant and equipment <sup>(d)</sup>	54
Identifiable intangible assets <sup>(e)</sup>	894
Other noncurrent assets	29
Accounts payable	(21)
Accrued compensation and related items	(10)
Other current liabilities	(22)
Other noncurrent liabilities	(11)
Noncurrent deferred tax liabilities <sup>(f)</sup>	(215)
Total net assets acquired	984
Goodwill <sup>(g)</sup>	978
<b>Total consideration</b>	<b>\$ 1,962</b>

<sup>(a)</sup> Short term investments include investments in debt securities that are classified as available-for-sale and measured at fair value.

<sup>(b)</sup> The fair value approximates the gross contractual amount of accounts receivable. The contractual amount not expected to be collected is immaterial.

Acquired inventory is comprised of finished goods, work in process and raw materials. The preliminary estimate of fair value of finished goods was determined based on net realizable value adjusted for the costs of the selling effort, a reasonable profit allowance for the selling effort, and estimated holding costs. The

<sup>(c)</sup> preliminary estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the selling effort, a reasonable profit allowance for the remaining manufacturing and selling effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value.

Property, plant and equipment is comprised of machinery and equipment, furniture and fixtures, computer equipment, leasehold improvements and

<sup>(d)</sup> construction in progress. The preliminary estimated fair value was primarily determined using a reproduction/replacement cost approach which measures the value of an asset by estimating the cost to acquire or construct comparable assets adjusted for age and condition of the asset.

Identifiable intangible assets primarily consist of developed technology rights, customer relationships, and trademarks and tradenames. The preliminary

<sup>(e)</sup> estimate of fair value of identifiable intangible assets is determined using the income approach, which includes a forecast of expected future cash flows. For additional information regarding identifiable intangible assets, see *Note 12. Goodwill and Other Intangible Assets*.

The acquisition was structured as a stock purchase and therefore we assumed the historical tax basis of Abaxis' assets and liabilities. The preliminary estimate of deferred tax effects resulting from the acquisition include the expected federal, state, and foreign tax consequences associated with temporary differences

<sup>(f)</sup> between the preliminary fair values of the assets acquired and liabilities assumed and the respective tax basis. The components of the Abaxis net deferred tax liability are included within amounts reported in *Note 8. Income Taxes*.

<sup>(g)</sup> Goodwill represents the excess of consideration transferred over the preliminary estimate of fair values of the assets acquired and liabilities assumed. It is

Table of Contents

allocated to our existing reportable segments and is primarily attributable to the future potential of the technology platforms, as well as cost and revenue synergies including market share capture, elimination of cost redundancies and gain of cost efficiencies, and intangible assets such as assembled workforce which are not separately recognizable. The primary strategic purpose of the acquisition was to enhance the company's existing product portfolio by strengthening Zoetis' presence in veterinary diagnostics. The goodwill recorded is not deductible for tax purposes. The allocation of goodwill to the reporting units is preliminary and will be completed as the company obtains the information necessary to complete the analysis, but no later than one year from the date of the acquisition.

The preliminary fair values are substantially complete subject to finalization of legal entity fair values (which may impact the fair values of identifiable intangible assets, deferred taxes and goodwill) and tax returns for the pre-acquisition period (which may impact the fair values of deferred taxes, income taxes payable and goodwill). Adjustments to the preliminary purchase price allocation identified during the measurement period, which will not exceed one year from the acquisition date, will be accounted for prospectively.

The company incurred acquisition related costs of approximately \$5 million for the three months ended March 31, 2019, which are included within *Restructuring charges and certain acquisition-related costs* on our condensed consolidated statements of income.

*Supplemental Pro Forma Information (Unaudited):*

The following table provides unaudited supplemental pro forma financial information as if the acquisition of Abaxis had occurred on January 1, 2017.

	Three Months Ended March 31, 2018
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)	2018
Revenue	<b>\$ 1,433</b>
Net income attributable to Zoetis Inc.	<b>322</b>

The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Zoetis and Abaxis. The supplemental pro forma financial information does not necessarily represent what the combined company's revenue or results of operations would have been had the acquisition been completed on January 1, 2017, nor do they intend to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Zoetis and Abaxis.

The unaudited supplemental pro forma financial information reflects primarily the following pro forma adjustments:

• Additional amortization expense of \$33 million for three months ended March 31, 2018, related to the preliminary fair value estimate of identified intangible assets acquired.

• Additional depreciation expense of \$1 million for the three months ended March 31, 2018, related to the preliminary estimate of fair value adjustments to property, plant and equipment acquired.

• Additional interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition, resulting in \$15 million added for the three months ended March 31, 2018.

• Adjustment related to the post merger share-based compensation expense of the replacement awards is \$3 million for the three months ended March 31, 2018.

• Applicable tax impact of the above adjustments based on the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred.

**6. Restructuring Charges and Other Costs Associated with Acquisitions, Cost-Reduction and Productivity Initiatives**

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. In connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as functions such as business technology, shared services and corporate operations.

During 2015, we launched a comprehensive operational efficiency program and a supply network strategy initiative. These initiatives focused on reducing complexity in our product portfolios, changing our selling approach in certain markets, reducing our presence in certain countries, and selling certain manufacturing sites over a long term period. As part of these initiatives, we reduced certain positions through divestitures, normal attrition and involuntary terminations.

Table of Contents

The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives are as follows:

	Three Months Ended <b>March 31,</b> <b>2019</b>	2018
(MILLIONS OF DOLLARS)		
Restructuring charges and certain acquisition-related costs:		
Integration costs <sup>(a)</sup>	\$ 1	\$ 1
Restructuring charges <sup>(b)(c)</sup> :		
Employee termination costs	4	1
<b>Total Restructuring charges and certain acquisition-related costs</b>	<b>\$ 5</b>	<b>\$ 2</b>

<sup>(a)</sup> Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

<sup>(b)</sup> The restructuring charges for the three months ended March 31, 2019 primarily relate to the acquisition of Abaxis.

The restructuring charges for the three months ended March 31, 2018 primarily relate to the supply network strategy initiative.

<sup>(c)</sup> The restructuring charges are associated with the following:

For the three months ended March 31, 2019 and March 31, 2018, Manufacturing/research/corporate of \$4 million and \$1 million, respectively.

The components of, and changes in, our restructuring accruals are as follows:

(MILLIONS OF DOLLARS)	Accrual <sup>(a)</sup>
Balance, December 31, 2018 <sup>(b)</sup>	\$ 45
<b>Provision</b>	<b>4</b>
<b>Utilization and other<sup>(c)</sup></b>	<b>(19 )</b>
<b>Balance, March 31, 2019<sup>(b)</sup></b>	<b>\$ 30</b>

<sup>(a)</sup> Changes in our restructuring accrual represents employee termination costs.

<sup>(b)</sup> At March 31, 2019, and December 31, 2018, included in *Accrued expenses* (\$13 million and \$27 million, respectively) and *Other noncurrent liabilities* (\$17 million and \$18 million, respectively).

<sup>(c)</sup> Includes adjustments for foreign currency translation.

## 7. Other (Income)/Deductions—Net

The components of *Other (income)/deductions—net* are as follows:

	Three Months Ended <b>March 31,</b> <b>2019</b>	2018
(MILLIONS OF DOLLARS)		
Royalty-related income	\$(5 )	\$(7 )
Interest income	(10 )	(6 )
Foreign currency loss <sup>(a)</sup>	—	8
Other, net	1	—
<b>Other (income)/deductions—net</b>	<b>\$(14 )</b>	<b>\$(5 )</b>

<sup>(a)</sup> Primarily driven by costs related to hedging and exposures to certain emerging market currencies.

## 8. Income Taxes

### A. Taxes on Income

Our effective tax rate was 18.1% for the three months ended March 31, 2019, compared with 16.1% for the three months ended March 31, 2018.

The higher effective tax rate for the three months ended March 31, 2019, was primarily attributable to:

the impact of the global intangible low taxed income (GILTI) tax, a new provision of the Tax Cuts and Jobs Act (the Tax Act), which became effective for the company in the first quarter of 2019;

changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings from operations and repatriation costs. The jurisdictional mix of earnings can vary as a result of repatriation decisions and operating fluctuations in the normal course of business and the impact of non-deductible items; and





Table of Contents

a \$4 million and \$8 million discrete tax benefit recorded in the first quarter of 2019 and 2018, respectively, related to a remeasurement of deferred taxes as a result of a change in non-U.S. statutory tax rates, partially offset by:

a \$13 million and \$8 million discrete tax benefit recorded in the first quarter of 2019 and 2018, respectively, related to the excess tax benefits for share-based payments.

**B. Deferred Taxes**

As of March 31, 2019, the total net deferred income tax liability of \$399 million is included in *Noncurrent deferred tax assets* (\$65 million) and *Noncurrent deferred tax liabilities* (\$464 million).

As of December 31, 2018, the total net deferred income tax liability of \$413 million is included in *Noncurrent deferred tax assets* (\$61 million) and *Noncurrent deferred tax liabilities* (\$474 million).

**C. Tax Contingencies**

As of March 31, 2019, the tax liabilities associated with uncertain tax positions of \$187 million (exclusive of interest and penalties related to uncertain tax positions of \$12 million) are included in *Noncurrent deferred tax assets* (\$3 million) and *Other taxes payable* (\$184 million).

As of December 31, 2018, the tax liabilities associated with uncertain tax positions of \$185 million (exclusive of interest and penalties related to uncertain tax positions of \$11 million) are included in *Noncurrent deferred tax assets* (\$3 million) and *Other taxes payable* (\$182 million).

Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.

Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

**9. Financial Instruments**

**A. Debt**

**Credit Facilities**

In December 2016, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year \$1.0 billion senior unsecured revolving credit facility (the credit facility). In December 2018, the maturity for the amended and restated revolving credit agreement was extended through December 2023. Subject to certain conditions, we have the right to increase the credit facility to up to \$1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. The credit facility also contains a clause which adds back to Adjusted Consolidated EBITDA, any operational efficiency restructuring charge (defined as charges recorded by the company during the period commencing on October 1, 2016 and ending December 31, 2019, related to operational efficiency initiatives), provided that for any twelve-month period such charges added back to Adjusted Consolidated EBITDA shall not exceed \$100 million in the aggregate.

The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of March 31, 2019, and December 31, 2018. There were no amounts drawn under the credit facility as of March 31, 2019, or December 31, 2018.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of March 31, 2019, we had access to \$73 million of lines of credit which expire at various times through 2019 and are generally renewed annually. There were no borrowings outstanding related to these facilities as of March 31, 2019 and \$9 million of borrowings outstanding related to these facilities as of December 31, 2018.

**Commercial Paper Program and Other Short-Term Borrowings**

In February 2013, we entered into a commercial paper program with a capacity of up to \$1.0 billion. As of March 31, 2019, and December 31, 2018, there was no commercial paper outstanding under this program. As of March 31, 2019, there were no short-term borrowings outstanding. As of December 31, 2018, we had \$9 million of short-term borrowings outstanding.



## Edgar Filing: Zoetis Inc. - Form 10-Q

### Table of Contents

#### Senior Notes and Other Long-Term Debt

On August 20, 2018, we issued \$1.5 billion aggregate principal amount of our senior notes (2018 senior notes), with an original issue discount of \$4 million. These notes are comprised of \$300 million aggregate principal amount of floating rate senior notes due 2021 (the "2018 floating rate senior notes"), and \$300 million aggregate principal amount of 3.250% senior notes due 2021, \$500 million aggregate principal amount of 3.900% senior notes due 2028 and \$400 million aggregate principal amount of 4.450% senior notes due 2048 (collectively, the "2018 fixed rate senior notes"). Net proceeds from this offering were partially used to pay down and terminate a revolving credit agreement and repay outstanding commercial paper, which were borrowed to finance a portion of the cash consideration for the acquisition of Abaxis (see *Note 5. Acquisitions and Divestitures*). The remainder of the net proceeds will be used for general corporate purposes.

On September 12, 2017, we issued \$1.25 billion aggregate principal amount of our senior notes (2017 senior notes), with an original issue discount of \$7 million. These notes are comprised of \$750 million aggregate principal amount of 3.000% senior notes due 2027 and \$500 million aggregate principal amount of 3.950% senior notes due 2047. Net proceeds from this offering were partially used in October 2017 to repay, prior to maturity, the aggregate principal amount of \$750 million, and a make-whole amount and accrued interest of \$4 million, of our 1.875% senior notes due 2018. The remainder of the net proceeds were used for general corporate purposes.

On November 13, 2015, we issued \$1.25 billion aggregate principal amount of our senior notes (2015 senior notes), with an original issue discount of \$2 million. On January 28, 2013, we issued \$3.65 billion aggregate principal amount of our senior notes (the 2013 senior notes offering) in a private placement, with an original issue discount of \$10 million.

The 2013, 2015, 2017 and 2018 senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the 2013, 2015, 2017 and 2018 senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the 2013, 2015 and 2017 senior notes and the 2018 fixed rate senior notes or any series, in whole or in part, at any time by paying a "make whole" premium, plus accrued and unpaid interest to, but excluding, the date of redemption. The 2018 floating rate senior notes are not redeemable at our option prior to their maturity date. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2013 senior notes due 2023 pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the 2013, 2015, 2017 and 2018 senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding 2013, 2015, 2017 and 2018 senior notes at a price equal to 101% of the aggregate principal amount of the 2013, 2015, 2017 and 2018 senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

The components of our long-term debt are as follows:

	<b>March</b>	<b>December</b>
(MILLIONS OF DOLLARS)	<b>31,</b>	<b>31,</b>
	<b>2019</b>	<b>2018</b>
3.450% 2015 senior notes due 2020	<b>\$ 500</b>	\$ 500
2018 floating rate (three-month USD LIBOR plus 0.44%) senior notes due 2021	<b>300</b>	300
3.250% 2018 senior notes due 2021	<b>300</b>	300
3.250% 2013 senior notes due 2023	<b>1,350</b>	1,350
4.500% 2015 senior notes due 2025	<b>750</b>	750
3.000% 2017 senior notes due 2027	<b>750</b>	750
3.900% 2018 senior notes due 2028	<b>500</b>	500
4.700% 2013 senior notes due 2043	<b>1,150</b>	1,150
3.950% 2017 senior notes due 2047	<b>500</b>	500
4.450% 2018 senior notes due 2048	<b>400</b>	400
	<b>6,500</b>	6,500
Unamortized debt discount / debt issuance costs	<b>(56 )</b>	(57 )
<i>Long-term debt, net of discount and issuance costs</i>	<b>\$6,444</b>	\$ 6,443

The fair value of our long-term debt was \$6,657 million and \$6,474 million as of March 31, 2019, and December 31, 2018, respectively, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from, or corroborated by, observable market data and Zoetis' credit rating (Level 2 inputs).

The principal amount of long-term debt outstanding, as of March 31, 2019, matures in the following years:

After

Edgar Filing: Zoetis Inc. - Form 10-Q

(MILLIONS OF DOLLARS)	2020	2021	2022	2023	2023	Total
Maturities	\$500	\$600	\$	—\$1,350	\$4,050	\$6,500

14 |

---

Table of ContentsInterest Expense

Interest expense, net of capitalized interest, was \$56 million and \$47 million, for the three months ended March 31, 2019, and March 31, 2018, respectively. Capitalized interest expense was \$3 million and \$2 million for the three months ended March 31, 2019, and March 31, 2018, respectively.

**B. Investments**

As part of the acquisition of Abaxis, we acquired short and long-term investments in debt securities (see *Note 5. Acquisitions and Divestitures*). These investments are classified as available-for-sale securities and, therefore, are measured at fair value at each reporting date. The changes in fair value are recognized in *Accumulated other comprehensive income/(loss)*. We utilized Level 2 inputs such as observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. The investment securities portfolio consists of debt securities that are investment grade. Information on investments in the debt securities, including the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale securities is as follows:

(MILLIONS OF DOLLARS)	Gross Unrealized							
	As of March 31, 2019				As of December 31, 2018			
	Amortized Cost	Gains	Losses	Fair Value	Amortized Cost	Gains	Losses	Fair Value
<b>Available-for-sale debt securities</b>								
Municipal Bonds	\$1	\$	—\$	—\$ 1	\$1	\$	—\$	—\$ 1
Corporate Bonds	64	—	—	64	100	—	—	100
Total debt securities	\$65	\$	—\$	—\$ 65	\$101	\$	—\$	—\$ 101

Maturities by Period<sup>(a)</sup>

(MILLIONS OF DOLLARS)	As of March 31, 2019				As of December 31, 2018			
	With 1 year	Over 1 to 5 years	Over 5 years	Total	With 1 year	Over 1 to 5 years	Over 5 years	Total
	<b>Available-for-sale debt securities</b>							
Municipal Bonds	\$1	\$	—\$	—\$ 1	\$1	\$	—\$	—\$ 1
Corporate Bonds	64	—	—	64	98	2	—	100
Total debt securities	\$65	\$	—\$	—\$ 65	\$99	\$ 2	\$	—\$ 101

**Available-for-sale debt securities**

<sup>(a)</sup> Long term investments are included in *Other noncurrent assets*.

**C. Derivative Financial Instruments**Foreign Exchange Risk

A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.

All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the condensed consolidated balance sheet. The derivative financial instruments primarily offset exposures in the Australian dollar, British pound, Canadian dollar, Chinese yuan, euro, and Japanese yen. Changes in fair value are reported in earnings or in *Accumulated other comprehensive income/(loss)*, depending on the nature and purpose of the financial instrument, as follows:

For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on forward-exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The aggregate notional amount of foreign exchange derivative financial instruments offsetting foreign currency exposures was \$1.1 billion and \$1.3 billion, as of March 31, 2019, and December 31, 2018, respectively. The vast majority of the foreign exchange derivative financial instruments mature within 60 days and all mature within one year.

For cross-currency interest rate swaps, which are designated as a hedge against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within *Accumulated other comprehensive loss* and reclassified into earnings when the foreign investment is sold or substantially liquidated. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (*Interest expense—net of capitalized interest*). The cash flows from these

## Edgar Filing: Zoetis Inc. - Form 10-Q

### Table of Contents

contracts are reflected within the investing section of our *condensed consolidated statement of cash flows*. The aggregate notional amount of cross-currency interest rate swap contracts was 507 million euro and 25 million swiss francs as of March 31, 2019, and 400 million euro as of December 31, 2018, with various terms of up to six years.

### Interest Rate Risk

The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing. In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in *Accumulated other comprehensive loss* and are recognized in earnings over the life of the future fixed-rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.

There were no outstanding interest rate swap contracts as of March 31, 2019 and December 31, 2018.

### Fair Value of Derivative Instruments

The classification and fair values of derivative instruments are as follows:

(MILLIONS OF DOLLARS)	Balance Sheet Location	Fair Value of Derivatives	
		March 31, 2019	December 31, 2018
<b>Derivatives Not Designated as Hedging Instruments</b>			
Foreign currency forward-exchange contracts	Other current assets	\$ 5	\$ 6
Foreign currency forward-exchange contracts	Other current liabilities	( 7 )	( 7 )
Total derivatives not designated as hedging instruments		\$ ( 2 )	\$ ( 1 )
<b>Derivatives Designated as Hedging Instruments:</b>			
Cross-currency interest rate swap contracts	Other current assets	\$ 7	\$ 3
Cross-currency interest rate swap contracts	Other non-current assets	15	8
Total derivatives designated as hedging instruments		22	11
Total derivatives		\$ 20	\$ 10

The company's cross-currency interest rate swaps are subject to master netting arrangements to mitigate credit risk by permitting net settlement of transactions with the same counterparty. We may also enter into collateral security arrangements with certain of our counterparties to exchange cash collateral when the net fair value of certain derivative instruments fluctuates from contractually established thresholds. At March 31, 2019, there was \$8 million of collateral received related to the long-term cross-currency interest rate swaps.

We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.

The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in *Other (income)/deductions—net*, are as follows:

(MILLIONS OF DOLLARS)	Three Months Ended March 31, 2019	2018
Foreign currency forward-exchange contracts	\$ ( 4 )	\$ 10

These amounts were substantially offset in *Other (income)/deductions—net* by the effect of changing exchange rates on the underlying foreign currency exposures.

The amounts of unrecognized net gains on cross-currency interest rate swap contracts, recorded, net of tax, in *Accumulated other comprehensive income/(loss)*, are as follows:

Three  
Months  
Ended  
March 31,

Edgar Filing: Zoetis Inc. - Form 10-Q

(MILLIONS OF DOLLARS)

**2019** 2018

Cross-currency interest rate swap contracts **\$ 18** \$ —

16 |

---

## Edgar Filing: Zoetis Inc. - Form 10-Q

### Table of Contents

Gains on cross-currency interest rate swap contracts, recognized within *Interest expense, net of capitalized interest*, are as follows:

	Three Months Ended <b>March 31,</b> <b>2019</b>						
(MILLIONS OF DOLLARS)	<b>2018</b>						
Cross-currency interest rate swap contracts	<b>\$ 4</b>	<b>\$</b>	<b>—</b>				

The net amount of deferred gains/(losses) related to derivative instruments designated as cash flow hedges that is expected to be reclassified from *Accumulated other comprehensive loss* into earnings over the next 12 months is insignificant.

### **10. Leases**

We have facilities, vehicles and equipment under various non-cancellable operating leases with third parties. These leases generally have remaining terms ranging from one to 15 years, inclusive of renewal options that are reasonably certain of exercise.

Supplemental information for operating leases is as follows:

	<b>March 31, 2019</b>
(MILLIONS OF DOLLARS, EXCEPT LEASE TERM AND DISCOUNT RATE AMOUNTS)	<b>2019</b>
<b>Supplemental Income Statement information for operating leases</b>	
Operating lease expense	\$9
Variable lease payments not included in the measurement of lease liabilities	4
Short-term lease payments not included in the measurement of lease liabilities	3
<b>Supplemental Cash Flow information for operating leases</b>	
Cash paid for amounts included in the measurement of lease liabilities	\$9
Lease obligations obtained in exchange for right-of-use assets (non-cash)	176
<b>Supplemental Balance Sheet information for operating leases</b>	
Operating lease right of use assets	\$158
<b>Operating lease liabilities</b>	
Operating lease liabilities - current	\$33
Operating lease liabilities - noncurrent	134
<b>Total operating lease liabilities</b>	<b>\$167</b>
Weighted-average remaining lease term—operating leases (years)	6.69
Weighted-average discount rate—operating leases	3.69 %

Future minimum lease payments under non-cancellable operating lease contracts as of March 31, 2019, are as follows:

						Total	Less:			
						After Lease	Imputed			
(MILLIONS OF DOLLARS)	2019 <sup>(a)</sup>	2020	2021	2022	2023	2023	Payments	Interest	Total	
Maturities	\$ 28	\$ 34	\$ 28	\$ 24	\$ 19	\$ 59	\$ 192	\$ (25 )	\$167	

<sup>(a)</sup> 2019 excludes the three months ended March 31, 2019

Future minimum lease payments under non-cancellable operating lease contracts as of December 31, 2018, in accordance with the superceded leasing standard, are as follows:

						After		
(MILLIONS OF DOLLARS)	2019	2020	2021	2022	2023	2023	Total	
Maturities	\$ 38	\$ 30	\$ 24	\$ 21	\$ 15	\$ 45	\$173	

Total rent expense, net of sublease rental income, in accordance with the superceded leasing standard, was approximately \$45 million in 2018.





Table of Contents**Lease Accounting Policy**

Below are the significant accounting policies updated as of January 1, 2019, as a result of the adoption of the new lease accounting guidance.

For additional information, see *Note 3. Accounting Standards*.

We determine if a contract contains a lease at inception. Our current portfolio includes only operating leases which are recorded as a right of use asset, as of the lease commencement date, in an amount equal to the present value of future payments over the lease term. We have elected not to recognize right of use assets and lease liabilities for short-term leases of vehicles and equipment with a lease term of twelve months or less.

Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. A corresponding lease liability is recorded within *other current liabilities* and *operating lease liabilities*. The present value of future payments is discounted using the rate implicit in the lease, when available. When the implicit rate is not available, as is frequently the case with our lease portfolio, the present value is calculated using our incremental borrowing rate, as determined as of the commencement date. The incremental borrowing rate represents the rate of interest that we would expect to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. As we do not borrow on a collateralized basis, our non-collateralized borrowing rate is used as an input in deriving the incremental borrowing rate.

Fixed lease payments are recognized on straight-line basis over the lease term, while variable payments are recognized in the period incurred.

Variable lease payments include real estate taxes and charges for other nonlease services due to lessors that are not dependent on an index or rate and utilization based charges associated with fleet vehicles.

Our real estate and fleet lease contracts may include fixed consideration attributable to both lease and non-lease components, including non-lease services provided by the vendor, which are accounted for as a single fixed minimum payment. For leases of certain classes of machinery and equipment, contract consideration is allocated to lease and non-lease components on the basis of relative standalone price.

**11. Inventories**

The components of inventory are as follows:

	March 31, 2019	December 31, 2018
(MILLIONS OF DOLLARS)		
Finished goods	\$655	\$ 744
Work-in-process	523	481
Raw materials and supplies	183	166
<i>Inventories</i>	<b>\$1,361</b>	\$ 1,391

**12. Goodwill and Other Intangible Assets****A. Goodwill**

The components of, and changes in, the carrying amount of goodwill are as follows:

(MILLIONS OF DOLLARS)	U.S.	International	Total
Balance, December 31, 2018	\$ 1,265	\$ 1,254	\$ 2,519
Additions	—	—	—
Other <sup>(a)</sup>	1	2	3
<b>Balance, March 31, 2019</b>	<b>\$ 1,266</b>	<b>\$ 1,256</b>	<b>\$ 2,522</b>

<sup>(a)</sup> Includes a measurement period adjustment related to the acquisition of Abaxis and adjustments for foreign currency translation.

The gross goodwill balance was \$3,058 million and \$3,055 million as of March 31, 2019, and December 31, 2018, respectively. Accumulated goodwill impairment losses were \$536 million as of March 31, 2019, and December 31, 2018.

**B. Other Intangible Assets**

The components of identifiable intangible assets are as follows:

	As of March 31, 2019			As of December 31, 2018		
	Gross Carrying Amount	Accumulated Amortization	Identifiable Intangible Assets Less Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization	Identifiable Intangible Assets Less Accumulated Amortization
(MILLIONS OF DOLLARS)						
Finite-lived intangible assets:						
Developed technology rights <sup>(a)</sup>	\$1,856	\$ (559)	\$ 1,297	\$1,854	\$ (523)	\$ 1,331
Brands	213	(157)	56	212	(154)	58
Trademarks and trade names <sup>(a)</sup>	166	(53)	113	166	(51)	115
Other	413	(197)	216	412	(178)	234
Total finite-lived intangible assets	2,648	(966)	1,682	2,644	(906)	1,738
Indefinite-lived intangible assets:						
In-process research and development	196	—	196	197	—	197
Brands	37	—	37	37	—	37
Trademarks and trade names	67	—	67	67	—	67
Product rights	7	—	7	7	—	7
Total indefinite-lived intangible assets	307	—	307	308	—	308
Identifiable intangible assets	\$2,955	\$ (966)	\$ 1,989	\$2,952	\$ (906)	\$ 2,046

<sup>(a)</sup> In connection with the acquisition of Abaxis in 2018, the company recorded \$894 million of intangible assets, as shown in the table below, representing the preliminary fair value at the acquisition date. See Note 5. *Acquisitions and Divestitures* for additional information.

(MILLIONS OF DOLLARS)	Gross Carrying Amount	Weighted-average Life (years)
	Finite-lived intangible assets:	
Developed technology rights	\$ 610	10
Trademarks and tradenames	104	20
Other	180	4
<b>Total</b>	<b>\$ 894</b>	

**C. Amortization**

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in *Amortization of intangible assets* as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in *Cost of sales, Selling, general and administrative expenses* or *Research and development expenses*, as appropriate. Total amortization expense for finite-lived intangible assets was \$58 million and \$25 million for three months ended March 31, 2019, and March 31, 2018, respectively.

**13. Share-based Payments**

The company may grant a variety of share-based payments under the Zoetis 2013 Equity and Incentive Plan (the Equity Plan) to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.

The components of share-based compensation expense are as follows:

(MILLIONS OF DOLLARS)	Three Months Ended March 31,	
	2019	2018
Stock options / stock appreciation rights	\$3	\$ 2
RSUs / DSUs <sup>(a)</sup>	12	7

## Edgar Filing: Zoetis Inc. - Form 10-Q

PSUs 3 2  
 Share-based compensation expense—total **\$18** \$ 11

(a) For the three months ended March 31, 2019, includes share-based compensation expense of \$5 million related to the acquisition of Abaxis, for the post-merger service period. For additional details, see *Note 5. Acquisitions and Divestitures*.

(b) Amounts capitalized to inventory were insignificant.

During the three months ended March 31, 2019, the company granted 436,746 stock options with a weighted-average exercise price of \$87.51 per stock option and a weighted-average fair value of \$21.78 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 2.57%; expected dividend yield of 0.75%; expected stock price volatility of 23.10%; and expected term of 5.7 years. In general, stock options vest after three years of continuous service and the values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into *Cost of sales, Selling, general and administrative expenses, or Research and development expenses*, as appropriate.

During the three months ended March 31, 2019, the company granted 355,747 RSUs, with a weighted-average grant date fair value of \$87.50 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs vest after three years of continuous service from the grant date and the values generally are amortized on a straight-line basis over the vesting term into *Cost of sales, Selling, general and administrative expenses, or Research and development expenses*, as appropriate.

During the three months ended March 31, 2019, the company granted 190,170 PSUs with a weighted-average grant date fair value of \$101.51 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 companies, which were 20.3% and 25.3%, respectively. Depending on the company's Relative TSR performance at the end of the performance period, the recipient may earn between 0% and 200% of the target number of units. Vested units are settled in shares of the company's common stock. PSU values are amortized on a straight-line basis over the vesting term into *Cost of sales, Selling, general and administrative expenses, or Research and development expenses*, as appropriate.

### 14. Stockholders' Equity

Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.

In December 2016, the company's Board of Directors authorized a \$1.5 billion share repurchase program. As of March 31, 2019, there was approximately \$151 million remaining under this authorization. In December 2018, the company's Board of Directors authorized an additional \$2.0 billion share repurchase program. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs.

Changes in common shares and treasury stock were as follows:

(MILLIONS)	Common Shares Issued <sup>(a)</sup>	Treasury Stock <sup>(a)</sup>
Balance, December 31, 2017	501.89	15.76
Share-based compensation	—	(0.99)
Share repurchase program	—	2.40
Balance, March 31, 2018	501.89	17.17
Balance, December 31, 2018	501.89	22.33
<b>Share-based compensation</b>	<b>—</b>	<b>(1.14)</b>
<b>Share repurchase program</b>	<b>—</b>	<b>1.67</b>
<b>Balance, March 31, 2019</b>	<b>501.89</b>	<b>22.87</b>

<sup>(a)</sup> Shares may not add due to rounding.

## Edgar Filing: Zoetis Inc. - Form 10-Q

### Table of Contents

Upon reissuance of treasury stock, differences between the proceeds from reissuance and the cost of the treasury stock that result in gains are recorded in *Additional paid-in capital*. Losses are recorded in *Additional paid-in capital* to the extent that they can offset previously recorded gains. If no such credit exists, the differences are recorded in *Retained earnings*.

### Accumulated other comprehensive income/(loss)

Changes, net of tax, in accumulated other comprehensive loss, excluding noncontrolling interests, were as follows:

	Cash Flow	Net Investment	Currency Translation Adjustments	Other Currency Translation Benefit Plans	Accumulated Other Comprehensive (Loss)/Income
(MILLIONS OF DOLLARS)					
Balance, December 31, 2017	\$ (3 )	\$ —	\$ (487 )	\$ (15 )	\$ (505 )
Other comprehensive income, net of tax	—	—	76	—	76
Balance, March 31, 2018	\$ (3 )	\$ —	\$ (411 )	\$ (15 )	\$ (429 )
Balance, December 31, 2018	\$ (4 )	\$ 10	\$ (621 )	\$ (14 )	\$ (629 )
<b>Other comprehensive income, net of tax</b>	<b>—</b>	<b>8</b>	<b>23</b>	<b>—</b>	<b>31</b>
<b>Balance, March 31, 2019</b>	<b>\$ (4 )</b>	<b>\$ 18</b>	<b>\$ (598 )</b>	<b>\$ (14 )</b>	<b>\$ (598 )</b>

## 15. Earnings per Share

The following table presents the calculation of basic and diluted earnings per share:

	Three Months Ended <b>March 31,</b>	
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	<b>2019</b>	2018
<b>Numerator</b>		
Net income before allocation to noncontrolling interests	<b>\$312</b>	\$350
Less: Net loss attributable to noncontrolling interests	—	(2 )
Net income attributable to Zoetis Inc.	<b>\$312</b>	\$352
<b>Denominator</b>		
Weighted-average common shares outstanding	<b>479.6</b>	485.9
Common stock equivalents: stock options, RSUs, PSUs and DSUs	<b>3.5</b>	3.9
Weighted-average common and potential dilutive shares outstanding	<b>483.1</b>	489.8
Earnings per share attributable to Zoetis Inc. stockholders—basic	<b>\$0.65</b>	\$0.72
Earnings per share attributable to Zoetis Inc. stockholders—diluted	<b>\$0.65</b>	\$0.72

The number of stock options outstanding under the company's Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were de minimis for both the three months ended March 31, 2019 and March 31, 2018.

## 16. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see *Note 8. Income Taxes*.

### A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

- Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
- Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
- Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
- Government investigations, which can involve regulation by national, state and local government agencies in the United States and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

20 |

---

Table of Contents

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader's judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

Ulianopolis, Brazil

In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.

The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.

At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area. On March 5, 2015, we presented our response to the prosecutor's proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit, by July 10, 2019, a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. We are in the process of coordinating with the other defendants with respect to the preparation of a response to the Prosecutor's order.

Lascadoil Contamination in Animal Feed

An investigation by the U.S. Food and Drug Administration (FDA) and the Michigan Department of Agriculture is ongoing to determine how lascadoil, oil for industrial use, made its way into the feed supply of certain turkey and hog feed mills in Michigan. The contaminated feed is believed to have caused the deaths of approximately 50,000 turkeys and the contamination (but not death) of at least 20,000 hogs in August 2014. While it remains an open question as to how the lascadoil made its way into the animal feed, the allegations are that lascadoil intended to be sold for reuse as biofuel was inadvertently sold to producers of soy oil, who in turn, unknowingly sold the contaminated soy oil to fat recycling vendors, who then sold the contaminated soy oil to feed mills for use in animal feed. Indeed, related to the FDA investigation, Shur-Green Farms LLC, a producer of soy oil, recalled certain batches of soy oil allegedly contaminated with lascadoil on October 13, 2014. During the course of its investigation, the FDA identified the process used to manufacture Zoetis' Avatec® (lasalocid sodium) and Bovatec® (lasalocid sodium) products as one possible source of the lascadoil, since lascadoil contains small amounts of lasalocid, the active ingredient found in both products. Zoetis has historically sold any and all industrial lascadoil byproduct to an environmental company specializing in waste disposal. The environmental company is contractually obligated to incinerate the lascadoil or resell it for use in biofuel. Under the terms





Table of Contents

of the agreement, the environmental company is expressly prohibited from reselling the lascadoil to be used as a component in food. The FDA inspected the Zoetis site where Avatec and Bovatec are manufactured, and found no evidence that Zoetis was involved in the contamination of the animal feed.

On March 10, 2015, plaintiffs Restaurant Recycling, LLC (Restaurant Recycling) and Superior Feed Ingredients, LLC (Superior), both of whom are in the fat recycling business, filed a complaint in the Seventeenth Circuit Court for the State of Michigan against Shur-Green Farms alleging negligence and breach of warranty claims arising from their purchase of soy oil allegedly contaminated with lascadoil. Plaintiffs resold the allegedly contaminated soy oil to turkey feed mills for use in feed ingredient. Plaintiffs also named Zoetis as a defendant in the complaint alleging that Zoetis failed to properly manufacture its products and breached an implied warranty that the soy oil was fit for use at turkey and hog mills. Zoetis was served with the complaint on June 3, 2015, and we filed our answer, denying all allegations, on July 15, 2015. On August 10, 2015, several of the turkey feed mills filed a joint complaint against Restaurant Recycling, Superior, Shur-Green Farms and others, alleging claims for negligence, misrepresentation, and breach of warranty, arising out of their alleged purchase and use of the contaminated soy oil. The complaint raises only one count against Zoetis for negligence. We filed an answer to the complaint on November 2, 2015, denying the allegation. On May 16, 2016, two additional turkey producers filed a complaint in the Seventeenth Circuit Court for the State of Michigan against the company, Restaurant Recycling, Superior, Shur-Green Farms and others, alleging claims for negligence and breach of warranties. We filed an answer to the complaint on June 20, 2016, denying the allegations. The Court has consolidated all three cases in Michigan for purposes of discovery and disposition. On July 28, 2017, we filed a motion for summary disposition on the grounds that no genuine issues of material fact exist and that Zoetis is entitled to judgment as a matter of law. On October 19, 2017, the Court granted our motion and dismissed all claims against Zoetis. On October 31, 2017, the plaintiffs filed motions for reconsideration of the Court's decision granting summary disposition. The Court, denied all such motions on December 6, 2017, for the same reasons cited in the Court's original decision. On December 27, 2017, the plaintiffs filed a request with the Michigan Court of Appeals seeking an interlocutory (or interim) appeal of the lower Court's decision, which we opposed on January 17, 2018. On July 5, 2018, the Court of Appeals denied the plaintiffs' request for an interlocutory appeal. The case has been remanded back to the lower Court, where it will proceed to trial (unless settled) without Zoetis. The plaintiffs will have the option to seek an appeal of the lower Court's decision granting Zoetis' motion for summary disposition after the final adjudication of the case.

Other Matters

On February 14, 2019, the General Court of the European Union (General Court) annulled the January 11, 2016 decision of the European Commission (EC) that selective tax advantages granted by Belgium under its "excess profit" tax scheme constitute illegal state aid. On April 26, 2019, the EC announced that it will appeal the decision of the General Court. Due to the uncertainty with respect to the outcome of the appeal to be filed by the EC, the company has not reflected any potential benefits associated with the decision of the General Court in its consolidated financial statements as of March 31, 2019. We will continue to monitor the developments of the appeal and its ultimate resolution.

The European Commission published a decision on alleged competition law infringements by several human health pharmaceutical companies on June 19, 2013. One of the involved legal entities is Alpharma LLC (previously having the name Zoetis Products LLC). Alpharma LLC's involvement is solely related to its human health activities prior to Pfizer's acquisition of King/Alpharma. Zoetis paid a fine in the amount of Euro 11 million (approximately \$14 million) and was reimbursed in full by Pfizer in accordance with the Global Separation Agreement between Pfizer and Zoetis, which provides that Pfizer is obligated to indemnify Zoetis for any liabilities arising out of claims not related to its animal health assets. We filed an appeal of the decision on September 6, 2013, to the General Court of the European Union. On September 8, 2016, the General Court upheld the decision of the European Commission. On November 25, 2016, we filed an appeal to the Court of Justice of the European Union. On January 24, 2019, the Court heard oral argument on the merits of the appeal, and we now await the Court's decision.

**B. Guarantees and Indemnifications**

In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2019, recorded amounts for the estimated fair value of these indemnifications were not significant.

**17. Segment Information**Operating Segments

We manage our operations through two geographic operating segments: the United States and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives, animal health diagnostics and other pharmaceuticals, for both livestock and companion animal customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

*Other business activities*, includes our Client Supply Services (CSS) contract manufacturing results, our human health diagnostics business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances,



Table of Contents

U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.

*Corporate*, includes platform functions such as business technology, facilities, legal, finance, human resources, business development, and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

Certain transactions and events such as (i) *Purchase accounting adjustments*, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) *Acquisition-related activities*, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) *Certain significant items*, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.

*Other unallocated* includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with business technology and finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

Table of Contents

(MILLIONS OF DOLLARS)	Earnings		Depreciation and Amortization <sup>(a)</sup>	
	Three Months Ended		Three Months Ended	
	<b>March 31,</b> <b>2019</b>	2018	<b>March 31,</b> <b>2019</b>	2018
<b><u>U.S.</u></b>				
Revenue	<b>\$718</b>	\$634		
Cost of sales	<b>147</b>	140		
Gross profit	<b>571</b>	494		
Gross margin	<b>79.5 %</b>	77.9 %		
Operating expenses	<b>110</b>	96		
Other (income)/deductions	—	—		
U.S. Earnings	<b>461</b>	398	<b>\$ 10</b>	\$ 8
<b><u>International</u></b>				
Revenue <sup>(b)</sup>	<b>718</b>	726		
Cost of sales	<b>210</b>	234		
Gross profit	<b>508</b>	492		
Gross margin	<b>70.8 %</b>	67.8 %		
Operating expenses	<b>132</b>	133		
Other (income)/deductions	—	1		
International Earnings	<b>376</b>	358	<b>13</b>	11
<b>Total operating segments</b>	<b>837</b>	756	<b>23</b>	19
Other business activities	<b>(80 )</b>	(81 )	<b>5</b>	5
Reconciling Items:				
Corporate	<b>(162 )</b>	(153 )	<b>14</b>	13
Purchase accounting adjustments	<b>(66 )</b>	(23 )	<b>55</b>	23
Acquisition-related costs	<b>(5 )</b>	(1 )	—	—
Certain significant items <sup>(c)</sup>	<b>(70 )</b>	(3 )	—	—
Other unallocated	<b>(73 )</b>	(78 )	<b>1</b>	—
<b>Total Earnings<sup>(d)</sup></b>	<b>\$381</b>	\$417	<b>\$ 98</b>	\$ 60

(a) Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

(b) Revenue denominated in euros was \$181 million and \$184 million for the three months ended March 31, 2019, and March 31, 2018, respectively.

(c) For the three months ended March 31, 2019, primarily represents a change in estimate related to inventory costing of \$68 million, and consulting fees of \$2 million related to our supply network strategy.

For the three months ended March 31, 2018, primarily represents: (i) employee termination costs and consulting fees related to our supply network strategy, and (ii) a charge related to the implementation of new accounting guidance as a result of the enactment of the Tax Act.

(d) Defined as income before provision for taxes on income.

Table of Contents

**Report of Independent Registered Public Accounting Firm**

To the Stockholders and Board of Directors

Zoetis Inc.:

*Results of Review of Interim Financial Information*

We have reviewed the condensed consolidated balance sheet of Zoetis Inc. and subsidiaries (the Company) as of March 31, 2019, the related condensed consolidated statements of income, comprehensive income, equity and cash flows for the three-month periods ended March 31, 2019 and March 31, 2018, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2018, and the related consolidated statements of income, comprehensive income, equity, and cash flows for the year then ended (not presented herein); and in our report dated February 14, 2019, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2018, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

*Basis for Review Results*

This consolidated interim financial information is the responsibility of the Company's management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ KPMG LLP

Short Hills, New Jersey

May 2, 2019

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations****Overview of our business**

We are a global leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines, and diagnostic products with a focus on both livestock and companion animals. For more than 65 years, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them.

We manage our operations through two geographic operating segments: the United States (U.S.) and International. Within each of these operating segments, we offer a diversified product portfolio for both livestock and companion animal customers in order to capitalize on local and regional trends and customer needs. See Notes to Condensed Consolidated Financial Statements *Note 17. Segment Information*.

We directly market our products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and are a market leader in nearly all of the major regions in which we operate. Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, China and Mexico, we believe we are one of the largest animal health medicines and vaccines businesses as measured by revenue across emerging markets as a whole. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.

We believe our investments in one of the industry's largest sales organizations, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our research and development (R&D) efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so they remain relevant for our customers.

A summary of our 2019 performance compared with the comparable 2018 period follows:

	% Change			
	Three Months Ended <b>March 31,</b>		Related to	
(MILLIONS OF DOLLARS)	<b>2019</b>	2018	Total Exchange and Operational <sup>(a)</sup>	
Revenue	\$1,455	\$1,366	7	(4 ) 11
Net income attributable to Zoetis	312	352	(11)	(2 ) (9 )
Adjusted net income <sup>(a)</sup>	424	365	16	(2 ) 18

<sup>(a)</sup> Operational growth and adjusted net income are non-GAAP financial measures. See the *Non-GAAP financial measures* section of this Management's Discussion and Analysis (MD&A) for more information.

**Our operating environment**

For a description of our operating environment, including factors which could materially affect our business, financial condition, or future results, see "Our Operating Environment" in the MD&A of our 2018 Annual Report on Form 10-K. Set forth below are updates to certain of the factors disclosed in our 2018 Form 10-K.

**Quarterly Variability of Financial Results**

Our quarterly financial results are subject to variability related to a number of factors including but not limited to: weather patterns, herd management decisions, economic conditions, regulatory actions, competitive dynamics, disease outbreaks, product and geographic mix, timing of price increases and timing of investment decisions.

**Disease Outbreaks**

Sales of our livestock products could be adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase.

**Foreign Exchange Rates**

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 100 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the three months ended March 31, 2019, approximately 46% of our revenue was denominated in foreign currencies. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign currencies, including the euro, Brazilian real, Chinese renminbi, Canadian dollar, Australian dollar, U.K. pound and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of goods and expenses, and consequently, net income. Exchange rate fluctuations may also have an impact beyond our reported financial results and directly impact operations. These fluctuations may affect the ability to buy and sell our goods and services between markets impacted by significant exchange rate variances. For the three months ended March 31, 2019, approximately 54% of our total revenue was in U.S. dollars. Our year-over-year total revenue growth was unfavorably impacted by approximately 4% from changes in foreign currency values relative to the U.S. dollar.



Table of Contents**Non-GAAP financial measures**

We report information in accordance with U.S. generally accepted accounting principles (GAAP). Management also measures performance using non-GAAP financial measures that may exclude certain amounts from the most directly comparable GAAP measure. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP financial measures have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors and may not be comparable to the calculation of similar measures of other companies. We present certain identified non-GAAP measures solely to provide investors with useful information to more fully understand how management assesses performance.

**Operational Growth**

We believe that it is important to not only understand overall revenue and earnings growth, but also “operational growth.” Operational growth is a non-GAAP financial measure defined as revenue or earnings growth excluding the impact of foreign exchange. This measure provides information on the change in revenue and earnings as if foreign currency exchange rates had not changed between the current and prior periods to facilitate a period-to-period comparison. We believe this non-GAAP measure provides a useful comparison to previous periods for the company and investors, but should not be viewed as a substitute for U.S. GAAP reported growth.

**Adjusted Net Income and Adjusted Earnings Per Share**

Adjusted net income and the corresponding adjusted earnings per share (EPS) are non-GAAP financial measures of performance used by management. We believe these financial measures are useful supplemental information to investors when considered together with our U.S. GAAP financial measures. We report adjusted net income to portray the results of our major operations, and the discovery, development, manufacture and commercialization of our products, prior to considering certain income statement elements. We define adjusted net income and adjusted EPS as net income attributable to Zoetis and EPS before the impact of purchase accounting adjustments, acquisition-related costs and certain significant items.

We recognize that, as an internal measure of performance, the adjusted net income and adjusted EPS measures have limitations, and we do not restrict our performance management process solely to these metrics. A limitation of the adjusted net income and adjusted EPS measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies. The adjusted net income and adjusted EPS measures are not, and should not be viewed as, a substitute for U.S. GAAP reported net income attributable to Zoetis and reported EPS. See the *Adjusted Net Income* section below for more information.

**Analysis of the condensed consolidated statements of income**

The following discussion and analysis of our statements of income should be read along with our condensed consolidated financial statements and the notes thereto included elsewhere in *Part I—Item 1* of this Quarterly Report on Form 10-Q.

	Three Months		
	Ended		%
	March 31,		
(MILLIONS OF DOLLARS)	2019	2018	
Revenue	\$1,455	\$1,366	7
Costs and expenses:			
Cost of sales <sup>(a)</sup>	518	447	16
% of revenue	35.6	% 32.7	%
Selling, general and administrative expenses <sup>(a)</sup>	369	338	9
% of revenue	25	% 25	%
Research and development expenses <sup>(a)</sup>	102	97	5
% of revenue	7	% 7	%
Amortization of intangible assets <sup>(a)</sup>	38	23	65
Restructuring charges and certain acquisition-related costs	5	2	*
Interest expense, net of capitalized interest	56	47	19
Other (income)/deductions—net	(14)	(5)	*
Income before provision for taxes on income	381	417	(9)
% of revenue	26	% 31	%
Provision for taxes on income	69	67	3
Effective tax rate	18.1	% 16.1	%
Net income before allocation to noncontrolling interests	312	350	(11)
Less: Net loss attributable to noncontrolling interests	—	(2)	(100)
Net income attributable to Zoetis	\$312	\$352	(11)
% of revenue	21	% 26	%

\* Calculation not meaningful.



Edgar Filing: Zoetis Inc. - Form 10-Q

Certain amounts and percentages may reflect rounding adjustments.

27 |

---

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in *Amortization of intangible assets* as these intangible assets benefit multiple business functions.

(a) Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in *Cost of sales, Selling, general and administrative expenses* or *Research and development expenses*, as appropriate.

## Revenue

### Three months ended March 31, 2019 vs. three months ended March 31, 2018

Total revenue increased by \$89 million, or 7%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, an increase of \$147 million, or 11%, on an operational basis. Operational revenue growth was comprised primarily of the following:

- the acquisition of Abaxis which contributed approximately 5%;
- price growth of approximately 4%;
- increased volume from in-line products, primarily driven by our key dermatology products of approximately 2%, partially offset by a decline of 1% from other in-line products; and
- volume growth from new products of approximately 1%.

Foreign exchange decreased reported revenue growth by approximately 4%.

## Costs and Expenses

### Cost of sales

	Three Months Ended		
	March 31, 2019	2018	% Change
(MILLIONS OF DOLLARS)			
Cost of sales	\$518	\$447	16
% of revenue	35.6 %	32.7 %	

Certain amounts and percentages may reflect rounding adjustments.

### Three months ended March 31, 2019 vs. three months ended March 31, 2018

Cost of sales as a percentage of revenue increased from 32.7% to 35.6% in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily as a result of:

- a change in estimate related to inventory costing;
- and
- the inclusion of Abaxis,

partially offset by:

- price increases;
- favorable product mix;
- continued cost improvements and efficiencies in our manufacturing network; and
- favorable foreign exchange.

### Selling, general and administrative expenses

	Three Months Ended		
	March 31, 2019	2018	% Change
(MILLIONS OF DOLLARS)			
Selling, general and administrative expenses	\$369	\$338	9
% of revenue	25 %	25 %	

Certain amounts and percentages may reflect rounding adjustments.

### Three months ended March 31, 2019 vs. three months ended March 31, 2018

Selling, general & administrative (SG&A) expenses increased by \$31 million, or 9%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily as a result of:

- the inclusion of Abaxis; and
- an increase in certain compensation-related expenses,

partially offset by:

- favorable foreign exchange.

Table of Contents**Research and development expenses**

	Three Months Ended		
	March 31,		%
(MILLIONS OF DOLLARS)	2019	2018	Change
Research and development expenses	\$102	\$97	5
% of revenue	7	% 7	%

Certain amounts and percentages may reflect rounding adjustments.

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

R&D expenses increased by \$5 million, or 5%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily as a result of:

- the inclusion of Abaxis; and
- an increase in certain compensation-related expenses, partially offset by:
  - favorable foreign exchange.

**Amortization of intangible assets**

	Three Months Ended		
	March 31,		%
(MILLIONS OF DOLLARS)	2019	2018	Change
Amortization of intangible assets	\$38	\$23	65

Certain amounts and percentages may reflect rounding adjustments.

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

Amortization of intangible assets increased by \$15 million, or 65%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018 as a result of certain intangible assets acquired in July 2018 as part of the acquisition of Abaxis.

**Restructuring charges and certain acquisition-related costs**

	Three Months Ended		
	March 31,		%
(MILLIONS OF DOLLARS)	2019	2018	Change
Restructuring charges and certain acquisition-related costs	\$5	\$2	*

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

During 2015, we launched a comprehensive operational efficiency program and a supply network strategy initiative. These initiatives focused on reducing complexity in our product portfolios, changing our selling approach in certain markets, reducing our presence in certain countries, and selling certain manufacturing sites over a long term period. As part of these initiatives, we reduced certain positions through divestitures, normal attrition and involuntary terminations.

Our acquisition-related costs primarily relate to restructuring charges for employees, assets and activities that will not continue in the future, as well as integration costs. The majority of these net restructuring charges are related to termination costs, but we also exited a number of distributor and other contracts and performed certain facility rationalization efforts. Our integration costs are generally comprised of consulting costs related to the integration of systems and processes, as well as product transfer costs.

For additional information regarding restructuring charges and acquisition-related costs, see Notes to Condensed Consolidated Financial Statements—*Note 6. Restructuring Charges and Other Costs Associated with Acquisitions, Cost-Reduction and Productivity Initiatives.*

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

Restructuring charges and certain acquisition-related costs increased by \$3 million in the three months ended March 31, 2019 compared with the three months ended March 31, 2018, primarily due to integration costs and employee termination costs incurred in the three months ended March 31, 2019, as a result of the acquisition of Abaxis in the third quarter of 2018.

Table of Contents***Interest expense, net of capitalized interest***

	Three Months Ended <b>March 31,</b>	<b>2019</b>	<b>2018</b>	<b>Change</b>	<b>%</b>
(MILLIONS OF DOLLARS)					
Interest expense, net of capitalized interest		\$56	\$47	19	

Certain amounts and percentages may reflect rounding adjustments.

***Three months ended March 31, 2019 vs. three months ended March 31, 2018***

Interest expense, net of capitalized interest, increased by \$9 million, or 19% in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, as a result of the issuance of \$1.5 billion aggregate principal amount of our senior notes in August 2018.

***Other (income)/deductions—net***

	Three Months Ended <b>March 31,</b>	<b>2019</b>	<b>2018</b>	<b>Change</b>	<b>%</b>
(MILLIONS OF DOLLARS)					
Other (income)/deductions—net		\$(14)	\$(5)	*	

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

***Three months ended March 31, 2019 vs. three months ended March 31, 2018***

The change in *Other (income)/deductions—net* from income of \$5 million in the three months ended March 31, 2018, to income of \$14 million in the three months ended March 31, 2019, is primarily a result of higher interest income due to higher short-term interest rates and higher cash balances in the three months ended March 31, 2019, as well as foreign currency losses in the three months ended March 31, 2018.

***Provision for taxes on income***

	Three Months Ended <b>March 31,</b>	<b>2019</b>	<b>2018</b>	<b>Change</b>	<b>%</b>
(MILLIONS OF DOLLARS)					
Provision for taxes on income		\$69	\$67	3	
Effective tax rate		18.1%	16.1%		

Certain amounts and percentages may reflect rounding adjustments.

***Three months ended March 31, 2019 vs. three months ended March 31, 2018***

Our effective tax rate was 18.1% for the three months ended March 31, 2019, compared with 16.1% for the three months ended March 31, 2018.

The higher effective tax rate for the three months ended March 31, 2019, was primarily attributable to:

• the impact of the global intangible low taxed income (GILTI) tax, a new provision of the Tax Cuts and Jobs Act (Tax Act), which became effective for the company in the first quarter of 2019;

• changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings from operations and repatriation costs. The jurisdictional mix of earnings can vary as a result of repatriation decisions and operating fluctuations in the normal course of business and the impact of non-deductible items; and

• a \$4 million and \$8 million discrete tax benefit recorded in the first quarter of 2019 and 2018, respectively, related to a remeasurement of deferred taxes as a result of a change in non-U.S. statutory tax rates, partially offset by:

• a \$13 million and \$8 million discrete tax benefit recorded in the first quarter of 2019 and 2018, respectively, related to the excess tax benefits for share-based payments.

**Operating Segment Results**

On a global basis, the mix of revenue between livestock and companion animal products was as follows:

(MILLIONS OF DOLLARS)	Three Months Ended		% Change		
	March 31, 2019	2018	Total	Related to Foreign Exchange	Operational
<b>U.S.</b>					
Livestock	\$273	\$292	(7)%	—%	(7)%
Companion animal	445	342	30%	—%	30%
	718	634	13%	—%	13%
<b>International</b>					
Livestock	434	478	(9)%	(8)%	(1)%
Companion animal	284	248	15%	(8)%	23%
	718	726	(1)%	(8)%	7%
<b>Total</b>					
Livestock	707	770	(8)%	(5)%	(3)%
Companion animal	729	590	24%	(3)%	27%
Contract manufacturing & human health diagnostics	19	6	*	*	*
	\$1,455	\$1,366	7%	(4)%	11%

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

Edgar Filing: Zoetis Inc. - Form 10-Q

Earnings by segment and the operational and foreign exchange changes versus the comparable prior year period were as follows:

(MILLIONS OF DOLLARS)	% Change				
	Three Months Ended		Related to		
	March 31, 2019	2018	Total Exchange	Operational	
<b><u>U.S.</u></b>					
Revenue	\$718	\$634	13	—	13
Cost of Sales	147	140	5	—	5
Gross Profit	571	494	16	—	16
Gross Margin	79.5 %	77.9 %			
Operating Expenses	110	96	15	—	15
Other (income)/deductions	—	—	—	—	—
U.S. Earnings	461	398	16	—	16
<b><u>International</u></b>					
Revenue	718	726	(1 )	(8 )	7
Cost of Sales	210	234	(10)	(10)	—
Gross Profit	508	492	3	(7 )	10
Gross Margin	70.8 %	67.8 %			
Operating Expenses	132	133	(1 )	(11)	10
Other (income)/deductions	—	1	*	*	*
International Earnings	376	358	5	(5 )	10
<b>Total operating segments</b>	<b>837</b>	<b>756</b>	<b>11</b>	<b>(2 )</b>	<b>13</b>
Other business activities	(80 )	(81 )	(1 )		
Reconciling Items:					
Corporate	(162 )	(153 )	6		
Purchase accounting adjustments	(66 )	(23 )	*		
Acquisition-related costs	(5 )	(1 )	*		
Certain significant items	(70 )	(3 )	*		
Other unallocated	(73 )	(78 )	(6 )		
Income before provision for taxes on income	\$381	\$417	(9 )		

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

**U.S. operating segment**

U.S. segment revenue increased by \$84 million, or 13%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, reflecting growth of approximately \$103 million in companion animal products and declines of approximately \$19 million in livestock products.

Companion animal revenue growth was driven primarily by the inclusion of Abaxis, and increased sales of parasiticides and the key dermatology portfolio.

Livestock revenue declined due to decreased sales of cattle and swine products, offset by increases in poultry products. Cattle and swine were both impacted by the timing of distributor purchasing patterns for medicated feed additive products. For poultry, growth was driven by increased sales of alternatives to antibiotic medicated feed additive products.

U.S. segment earnings increased by \$63 million, or 16%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily due to revenue growth and improved gross margins, partially offset by higher operating expenses.



**International operating segment**

International segment revenue decreased by \$8 million, or 1%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018. Operational revenue increased by \$50 million, or 7%, driven by growth of approximately \$56 million in companion animal products and declines of approximately \$6 million in livestock products.

Companion animal revenue growth resulted primarily from increased sales of the key dermatology portfolio across multiple international markets, the inclusion of Abaxis, and growth of certain in-line products, including Simparica®.

Livestock revenue decreased, driven primarily by a decline in swine sales due to the negative impact of African Swine Fever in China, partially offset by growth in the poultry, fish and sheep portfolios.

Additionally, segment revenue was unfavorably impacted by foreign exchange, which decreased revenue by approximately \$58 million, or 8%, primarily driven by the depreciation of the euro, Brazilian real, Turkish lira, Argentinian peso, Australian dollar and U.K. pound.

International segment earnings increased by \$18 million, or 5%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018. Operational earnings growth was \$37 million, or 10%, primarily due to higher revenue and improved gross margin partially offset by higher operating expenses.

**Other business activities**

Other business activities includes our Client Supply Services (CSS) contract manufacturing results, our human health diagnostics business and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the International segment.

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

Other business activities net loss decreased by \$1 million, or 1%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, reflecting revenue from the acquired Abaxis human health diagnostic business, partially offset by an increase in R&D costs due to the inclusion of Abaxis expenses and compensation-related costs.

**Reconciling items**

Reconciling items include certain costs that are not allocated to our operating segments results, such as costs associated with the following:

**Corporate**, which includes certain costs associated with business technology, facilities, legal, finance, human resources, business development and communications, among others. These costs also include certain compensation costs, certain procurement costs, and other miscellaneous operating expenses that are not charged to our operating segments, as well as interest income and expense;

Certain transactions and events such as (i) **Purchase accounting adjustments**, which includes expenses associated with the amortization of fair value adjustments to inventory, intangible assets, and property, plant and equipment; (ii) **Acquisition-related activities**, which includes costs for acquisition and integration; and (iii) **Certain significant items**, which includes non-acquisition-related restructuring charges, certain asset impairment charges, certain legal and commercial settlements, and costs associated with cost reduction/productivity initiatives; and

**Other unallocated**, which includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with business technology and finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.

**Three months ended March 31, 2019 vs. three months ended March 31, 2018**

Corporate expenses increased by \$9 million, or 6%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily due to higher interest expense, net of capitalized interest, associated with the additional debt issued in August 2018, and an increase in certain compensation costs not allocated to our operating segments, partially offset by favorable foreign exchange.

Other unallocated expenses declined by \$5 million, or 6%, in the three months ended March 31, 2019, compared with the three months ended March 31, 2018, primarily due to the favorable impact of foreign exchange, partially offset by the inclusion of Abaxis expenses.

See Notes to Condensed Consolidated Financial Statements—*Note 17. Segment Information* for further information.

**Adjusted net income****General description of adjusted net income (a non-GAAP financial measure)**

Adjusted net income is an alternative view of performance used by management, and we believe that investors' understanding of our performance is enhanced by disclosing this performance measure. The adjusted net income measure is an important internal measurement for us. Additionally, we measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how the adjusted net income measure is utilized:

• senior management receives a monthly analysis of our operating results that is prepared on an adjusted net income basis;



Table of Contents

- our annual budgets are prepared on an adjusted net income basis; and
- other goal setting and performance measurements.

***Purchase accounting adjustments***

Adjusted net income is calculated prior to considering certain significant purchase accounting impacts that result from business combinations and net asset acquisitions. These impacts, primarily associated with the acquisition of Abaxis (acquired in July 2018), the Pharmaq business (acquired in November 2015), certain assets of Abbott Animal Health (acquired in February 2015), King Animal Health (KAH) (acquired in 2011), Fort Dodge Animal Health (FDAH) (acquired in 2009), and Pharmacia Animal Health business (acquired in 2003), include amortization related to the increase in fair value of the acquired finite-lived intangible assets and depreciation related to the increase/decrease to fair value of the acquired fixed assets. Therefore, the adjusted net income measure includes the revenue earned upon the sale of the acquired products without considering the aforementioned significant charges.

While certain purchase accounting adjustments can occur through 20 or more years, this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by providing a degree of parity to internally developed intangible assets for which R&D costs previously have been expensed.

A completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through adjusted net income. These components of adjusted net income are derived solely from the impact of the items listed above. We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting revenue, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our adjusted net income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.

***Acquisition-related costs***

Adjusted net income is calculated prior to considering transaction and integration costs associated with significant business combinations or net asset acquisitions because these costs are unique to each transaction and represent costs that were incurred to acquire and integrate certain businesses as a result of the acquisition decision. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination result primarily from the need to eliminate duplicate assets, activities or employees—a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in the ordinary course of business.

The integration costs associated with a business combination may occur over several years, with the more significant impacts generally ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the regulated nature of the animal health medicines and vaccines business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the FDA and/or other regulatory authorities.

***Certain significant items***

Adjusted net income is calculated excluding certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be costs related to a major non-acquisition-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition-related cost-reduction and productivity initiatives; amounts related to disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; significant currency devaluation; the impact of adopting certain significant, event-driven tax legislation; or charges related to legal matters. See Notes to Condensed Consolidated Financial Statements—*Note 16. Commitments and Contingencies*. Our normal, ongoing defense costs or settlements of and accruals on legal matters made in the normal course of our business would not be considered certain significant items.

Table of Contents**Reconciliation**

A reconciliation of net income attributable to Zoetis, as reported under U.S. GAAP, to adjusted net income follows:

	Three Months Ended <b>March 31, %</b>		
(MILLIONS OF DOLLARS)	<b>2019</b>	2018	Change
GAAP reported net income attributable to Zoetis	<b>\$312</b>	\$352	(11 %)
Purchase accounting adjustments—net of tax	<b>46</b>	12	*
Acquisition-related costs—net of tax	<b>4</b>	1	*
Certain significant items—net of tax	<b>62</b>	—	*
Non-GAAP adjusted net income <sup>(a)</sup>	<b>\$424</b>	\$365	16 %

\*Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

The effective tax rate on adjusted pretax income is 18.8% and 18.2% for the three months ended March 31, 2019, and March 31, 2018, respectively. The higher effective tax rate for the three months ended March 31, 2019, compared with the three months ended March 31, 2018, was primarily attributable to (i) the impact of GILTI tax, a new provision to the Tax Act, which became effective for the company in the first quarter of 2019, (ii) changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, and (iii) a \$13 million and \$8 million discrete tax benefit recorded in the first quarter of 2019 and 2018, respectively, related to the excess tax benefits for share-based payments.

A reconciliation of reported diluted earnings per share (EPS), as reported under U.S. GAAP, to non-GAAP adjusted diluted EPS follows:

	Three Months Ended <b>March 31, %</b>		
	<b>2019</b>	2018	Change
Earnings per share—diluted			
GAAP reported EPS attributable to Zoetis—diluted	<b>\$0.65</b>	\$0.72	(10 %)
Purchase accounting adjustments—net of tax	<b>0.09</b>	0.03	*
Acquisition-related costs—net of tax	<b>0.01</b>	—	*
Certain significant items—net of tax	<b>0.13</b>	—	*
Non-GAAP adjusted EPS—diluted	<b>\$0.88</b>	\$0.75	17 %

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

(a) Diluted earnings per share was computed using the weighted-average common shares outstanding during the period plus the common stock equivalents related to stock options, restricted stock units, performance-vesting restricted stock units and deferred stock units.

Adjusted net income includes the following charges for each of the periods presented:

	Three Months Ended <b>March 31,</b>	
(MILLIONS OF DOLLARS)	<b>2019</b>	2018
Interest expense, net of capitalized interest	<b>\$56</b>	\$47
Interest income	<b>10</b>	6
Income taxes	<b>98</b>	81
Depreciation	<b>38</b>	33
Amortization	<b>5</b>	4

Table of Contents

Adjusted net income, as shown above, excludes the following items:

	Three Months Ended <b>March 31,</b>	
	<b>2019</b>	2018
<b>(MILLIONS OF DOLLARS)</b>		
<b>Purchase accounting adjustments:</b>		
Amortization and depreciation <sup>(a)</sup>	<b>\$52</b>	\$ 21
Cost of sales <sup>(b)</sup>	<b>14</b>	2
Total purchase accounting adjustments—pre-tax	<b>66</b>	23
Income taxes <sup>(c)</sup>	<b>20</b>	11
Total purchase accounting adjustments—net of tax	<b>46</b>	12
<b>Acquisition-related costs:</b>		
Integration costs	<b>1</b>	1
Restructuring costs	<b>4</b>	—
Total acquisition-related costs—pre-tax	<b>5</b>	1
Income taxes	<b>1</b>	—
Total acquisition-related costs—net of tax	<b>4</b>	1
<b>Certain significant items:</b>		
Supply network strategy <sup>(d)</sup>	<b>2</b>	2
Other <sup>(e)</sup>	<b>68</b>	1
Total certain significant items—pre-tax	<b>70</b>	3
Income taxes <sup>(c)</sup>	<b>8</b>	3
Total certain significant items—net of tax	<b>62</b>	0
<b>Total purchase accounting adjustments, acquisition-related costs, and certain significant items—net of tax</b>	<b>\$112</b>	\$ 13

Certain amounts may reflect rounding adjustments.

(a) Amortization and depreciation expenses related to *Purchase accounting adjustments* with respect to identifiable intangible assets and property, plant and equipment.

(b) Amortization and depreciation expense, as well as fair value adjustments to acquired inventory.

(c) Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

Income taxes in *Purchase accounting adjustments* also includes a tax benefit related to a remeasurement of deferred taxes as a result of a change in non-U.S. statutory tax rates, for both the three months ended March 31, 2019, and March 31, 2018.

Income taxes in *Certain significant items* also includes a net tax benefit related to a measurement-period adjustment to the provisional one-time mandatory deemed repatriation tax on the company's undistributed non-U.S. earnings, pursuant to the Tax Act, for the three months ended March 31, 2018.

(d) Represents consulting fees related to cost-reduction and productivity initiatives.

(e) For the three months ended March 31, 2019, primarily represents a change in estimate related to inventory costing.

Table of Contents

The classification of the above items excluded from adjusted net income are as follows:

(MILLIONS OF DOLLARS)	Three Months Ended <b>March 31,</b>	
	<b>2019</b>	2018
<b>Cost of sales:</b>		
Purchase accounting adjustments	<b>\$14</b>	\$ 2
Consulting fees	<b>2</b>	1
Other	<b>68</b>	—
<i>Total Cost of sales</i>	<b>84</b>	3
<b>Selling, general &amp; administrative expenses:</b>		
Purchase accounting adjustments	<b>18</b>	1
Other	<b>—</b>	1
<i>Total Selling, general &amp; administrative expenses</i>	<b>18</b>	2
<b>Research &amp; development expenses:</b>		
Purchase accounting adjustments	<b>—</b>	1
<i>Total Research &amp; development expenses</i>	<b>—</b>	1
<b>Amortization of intangible assets:</b>		
Purchase accounting adjustments	<b>34</b>	19
<i>Total Amortization of intangible assets</i>	<b>34</b>	19
<b>Restructuring charges/(reversals) and certain acquisition-related costs:</b>		
Integration costs	<b>1</b>	1
Employee termination costs	<b>4</b>	1
<i>Total Restructuring charges/(reversals) and certain acquisition-related costs</i>	<b>5</b>	2
<b>Provision for taxes on income</b>	<b>29</b>	14

**Total purchase accounting adjustments, acquisition-related costs, and certain significant items—net of tax** \$112 \$ 13

Certain amounts may reflect rounding adjustments.

**Analysis of the condensed consolidated statements of comprehensive income**

Substantially all changes in other comprehensive income for the periods presented are related to foreign currency translation adjustments. These changes result from the strengthening or weakening of the U.S. dollar as compared to the currencies in the countries in which we do business. The gains and losses associated with these changes are deferred on the balance sheet in *Accumulated other comprehensive loss* until realized.

**Analysis of the condensed consolidated balance sheets****March 31, 2019 vs. December 31, 2018**

For a discussion about the changes in *Cash and cash equivalents*, *Short-term borrowings*, and *Long-term debt, net of discount and issuance costs*, see “Analysis of financial condition, liquidity and capital resources” below.

*Short-term investments* decreased as a result of maturities of debt securities.

*Accounts receivable, less allowance for doubtful accounts* decreased as a result lower sales related to seasonality, partially offset by the timing of rebate payment to customers and the impact of foreign exchange.

The net change in *Operating lease right of use assets*, and *Operating lease liability* relates to the adoption of the new lease accounting standard, which became effective January 1, 2019. See Notes to Condensed Consolidated Financial Statements—*Note 3. Accounting Standards and Note 10. Leases*.

The net change in *Income taxes payable* primarily reflects adjustments to the accrual for the income tax provision for the first quarter of 2019.

See Notes to Condensed Consolidated Financial Statements—*Note 8. Income Taxes*.

*Accounts payable* decreased as a result of the timing of payments.

*Accrued expenses* decreased primarily as a result of payment of accrued expenses, including accrued interest and employee termination costs associated with the acquisition of Abaxis.

37 |

---

Table of Contents

*Accrued compensation and related items* decreased primarily due to payment of 2018 annual bonuses to eligible employees and 2018 employee savings plan contributions, partially offset by the pro rata accrual of similar items for 2019.

*Other current liabilities* increased primarily due to short-term lease liabilities as a result of the adoption of the new lease accounting standard, which became effective January 1, 2019, partially offset by the payment of contingent consideration related to the 2016 acquisition of certain intangible assets related to our livestock product portfolio and the 2018 acquisition of a manufacturing business in Ireland. See Notes to Condensed Consolidated Financial Statements—*Note 3. Accounting Standards* and *Note 10. Leases*.

For an analysis of the changes in *Total Equity*, see the Condensed Consolidated Statements of Equity and Notes to Condensed Consolidated Financial Statements—*Note 14. Stockholders' Equity*.

**Analysis of the condensed consolidated statements of cash flows**

(MILLIONS OF DOLLARS)	Three Months Ended		
	March 31, 2019	2018	% Change
Net cash provided by (used in):			
Operating activities	\$ 389	\$ 389	—
Investing activities	(23 )	(45 )	(49 )
Financing activities	(243 )	(262 )	(7 )
Effect of exchange-rate changes on cash and cash equivalents	3	8	(63 )
Net increase (decrease) in cash and cash equivalents	\$ 126	\$ 90	40

\*Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

***Operating activities******Three months ended March 31, 2019 vs. three months ended March 31, 2018***

Net cash provided by operating activities was \$389 million for each of the three months ended March 31, 2019, and March 31, 2018. The increase in net income after non-cash adjustments was offset by timing of payments in the ordinary course of business.

***Investing activities******Three months ended March 31, 2019 vs. three months ended March 31, 2018***

Our net cash used in investing activities was \$23 million for the three months ended March 31, 2019, compared with net cash used in investing activities of \$45 million for the three months ended March 31, 2018. The net cash used in investing activities for 2019 was primarily due to purchases of property, plant and equipment, partially offset by proceeds from maturities of debt securities and proceeds from cross-currency interest rate swaps. The net cash used in investing activities for 2018 was primarily due to purchases of property, plant and equipment, partially offset by proceeds from the 2017 sale of our manufacturing site in Guarulhos, Brazil.

***Financing activities******Three months ended March 31, 2019 vs. three months ended March 31, 2018***

Our net cash used in financing activities was \$243 million for the three months ended March 31, 2019, compared with net cash used in financing activities of \$262 million for the three months ended March 31, 2018. The net cash used in financing activities for 2019 was primarily attributable to the purchase of treasury shares, the payment of dividends, the payments of contingent consideration related to the 2016 acquisition of certain intangible assets related to our livestock product portfolio and the 2018 acquisition of a manufacturing business in Ireland, and payment of short-term borrowings. The net cash used in financing activities for 2018 was primarily attributable to the purchase of treasury shares and the payment of dividends.

**Analysis of financial condition, liquidity and capital resources**

While we believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our future cash needs, this may be subject to the environment in which we operate. Risks to our meeting future funding requirements include global economic conditions described in the following paragraph.

Global financial markets may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position, but there can be no assurance that a challenging economic environment or an economic downturn will not impact our liquidity or our ability to obtain future financing.

Table of Contents**Selected measures of liquidity and capital resources**

Certain relevant measures of our liquidity and capital resources follow:

	<b>March</b>	December
	<b>31,</b>	31,
(MILLIONS OF DOLLARS)	<b>2019</b>	2018
Cash and cash equivalents	<b>\$1,728</b>	\$ 1,602
Accounts receivable, net <sup>(a)</sup>	<b>970</b>	1,036
Long-term debt, net of discount and issuance costs	<b>6,444</b>	6,443
Working capital	<b>3,297</b>	3,176
Ratio of current assets to current liabilities	<b>4.05:1</b>	3.60:1

Accounts receivable are usually collected over a period of 45 to 75 days. For the three months ended March 31, 2019, compared with December 31, 2018, the number of days that accounts receivables are outstanding remained approximately the same. We regularly monitor our accounts receivable for collectability, particularly in markets where economic conditions remain uncertain. We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on such factors as past due aging, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.

For additional information about the sources and uses of our funds, see the *Analysis of the condensed consolidated balance sheets* and *Analysis of the condensed consolidated statements of cash flows* sections of this MD&A.

**Credit facility and other lines of credit**

In December 2016, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year \$1.0 billion senior unsecured revolving credit facility (the credit facility). In December 2018, the maturity for the amended and restated credit facility was extended through December 2023. Subject to certain conditions, we have the right to increase the credit facility to up to \$1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. The credit facility also contains a clause which adds back to Adjusted Consolidated EBITDA, any operational efficiency restructuring charge (defined as charges recorded by the company during the period commencing on October 1, 2016 and ending December 31, 2019, related to operational efficiency initiatives), provided that for any twelve-month period such charges added back to Adjusted Consolidated EBITDA shall not exceed \$100 million in the aggregate.

The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of March 31, 2019 and December 31, 2018. There were no amounts drawn under the credit facility as of March 31, 2019 or December 31, 2018.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of March 31, 2019, we had access to \$73 million of lines of credit which expire at various times through 2019, and are generally renewed annually. We had \$0 million, and \$9 million of borrowings outstanding related to these facilities as of March 31, 2019 and December 31, 2018.

**Domestic and international short-term funds**

Many of our operations are conducted outside the United States. The amount of funds held in the United States will fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of U.S. and international cash flows (both inflows and outflows). Actual repatriation of overseas funds can result in additional U.S. and local income taxes, such as U.S. state income taxes, local withholding taxes, and taxes on currency gains and losses. In addition, the recent changes imposed by the Tax Act resulted in a one-time deemed repatriation tax of previously untaxed accumulated and current earnings and profits of our foreign subsidiaries, which is payable over eight years, with the first installment due in 2019.

**Global economic conditions**

Challenging economic conditions in recent years have not had, nor do we anticipate that it will have, a significant impact on our liquidity. Due to our operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have the ability to meet our liquidity needs for the foreseeable future. As markets change, we continue to monitor our liquidity position. There can be no assurance that a challenging economic environment or a further economic downturn would not impact our ability to obtain financing in the future.

Table of Contents

**Debt**

On August 20, 2018, we issued \$1.5 billion aggregate principal amount of our senior notes (2018 senior notes), with an original issue discount of \$4 million. These notes are comprised of \$300 million aggregate principal amount of floating rate senior notes due 2021 (the "2018 floating rate senior notes"), and \$300 million aggregate principal amount of 3.250% senior notes due 2021, \$500 million aggregate principal amount of 3.900% senior notes due 2028 and \$400 million aggregate principal amount of 4.450% senior notes due 2048 (collectively, the "2018 fixed rate senior notes"). Net proceeds from this offering were partially used to pay down and terminate a revolving credit agreement and repay outstanding commercial paper, which were borrowed to finance a portion of the cash consideration for the acquisition of Abaxis (see Notes to Condensed Consolidated Financial Statements—*Note 5. Acquisitions and Divestitures*). The remainder of the net proceeds will be used for general corporate purposes.

On September 12, 2017, we issued \$1.25 billion aggregate principal amount of our senior notes (2017 senior notes), with an original issue discount of \$7 million. These notes are comprised of \$750 million aggregate principal amount of 3.000% senior notes due 2027 and \$500 million aggregate principal amount of 3.950% senior notes due 2047. Net proceeds from this offering were partially used in October 2017 to repay, prior to maturity, the aggregate principal amount of \$750 million, and a make-whole amount and accrued interest of \$4 million, of our 1.875% senior notes due 2018. The remainder of the net proceeds were used for general corporate purposes.

On November 13, 2015, we issued \$1.25 billion aggregate principal amount of our senior notes (2015 senior notes), with an original issue discount of \$2 million. On January 28, 2013, we issued \$3.65 billion aggregate principal amount of our senior notes (2013 senior notes) in a private placement, with an original issue discount of \$10 million.

The 2013, 2015, 2017 and 2018 senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale lease-back transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which (if not cured or waived), the 2013, 2015, 2017 and 2018 senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the 2013, 2015 and 2017 senior notes and the 2018 fixed rate senior notes of any series, in whole or in part, at any time by paying a "make whole" premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2013 senior notes due 2023 pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the 2013, 2015, 2017 and 2018 senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding 2013, 2015, 2017 and 2018 senior notes at a price equal to 101% of the aggregate principal amount of the 2013, 2015, 2017 and 2018 senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

The components of our long-term debt follow:

Description	Principal Amount	Interest Rate	Terms
2015 Senior Note due 2020	\$500 million	3.450%	Interest due semi annually, not subject to amortization, aggregate principal due on November 13, 2020
2018 Floating Rate Senior Note due 2021	\$300 million	Three-month USD LIBOR plus 0.44%	Interest due quarterly, not subject to amortization, aggregate principal due on August 20, 2021
2018 Senior Note due 2021	\$300 million	3.250%	Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2021
2013 Senior Note due 2023	\$1,350 million	3.250%	Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2023
2015 Senior Note due 2025	\$750 million	4.500%	Interest due semi annually, not subject to amortization, aggregate principal due on November 13, 2025
2017 Senior Note due 2027	\$750 million	3.000%	Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2027
2018 Senior Note due 2028	\$500 million	3.900%	Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2028
2013 Senior Note due 2043	\$1,150 million	4.700%	Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2043
2017 Senior Note due 2047	\$500 million	3.950%	Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2047
2018 Senior Note due 2048	\$400 million	4.450%	Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2048

**Credit Ratings**

Two major corporate debt-rating organizations, Moody's and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.





Table of Contents

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:

**Credit Ratings**

Two major corporate debt-rating organizations, Moody's and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:

Name of Rating Agency	Paper Rating	Long-term Debt		Date of Last Action
		Rating	Outlook	
Moody's	P-2	Baa1	Stable	August 2017
S&P	A-2	BBB	Stable	December 2016

**Share Repurchase Program**

In December 2016, the company's Board of Directors authorized a \$1.5 billion share repurchase program. As of March 31, 2019, there was approximately \$151 million remaining under this authorization. In December 2018, the company's Board of Directors authorized an additional \$2.0 billion share repurchase program. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs. Share repurchases may be executed through various means, including open market or privately negotiated transactions. During the first three months of 2019, approximately 2 million shares were repurchased.

**Off-balance sheet arrangements**

In the ordinary course of business and in connection with the sale of assets and businesses, we may indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 31, 2019, or December 31, 2018, recorded amounts for the estimated fair value of these indemnifications are not significant.

**New accounting standards**

Recently Issued Accounting Standards Not Adopted as of March 31, 2019.

In August, 2018, the FASB issued an accounting standards update which expands the scope of costs associated with cloud computing arrangements that must be capitalized. Under the new guidance, costs associated with implementing a cloud computing arrangement that is a service contract must be capitalized and expensed over the term of the hosting arrangement. The provisions of the update are effective beginning January 1, 2020 for interim and annual periods with early adoption permitted for any interim period after issuance of the update. We are currently assessing the timing of our adoption as well as the potential impact that the standard will have on our consolidated financial statements.

**Forward-looking statements and factors that may affect future results**

This report contains "forward-looking" statements. We generally identify forward-looking statements by using words such as "anticipate," "estimate," "could," "expect," "intend," "project," "plan," "predict," "believe," "seek," "continue," "outlook," "objective," "target," "may," "might," "will," "should," negative version of these words or comparable words or by using future dates in connection with any discussion of future performance, actions or events.

In particular, forward-looking statements include statements relating to our 2019 financial guidance, future actions, business plans or prospects, prospective products, product approvals or products under development, product supply disruptions, R&D costs, timing and likelihood of success, future operating or financial performance, future results of current and anticipated products and services, strategies, sales efforts, expenses, production efficiencies, production margins, anticipated timing of generic market entries, integration of acquired businesses, interest rates, tax rates, changes in tax regimes and laws, foreign exchange rates, growth in emerging markets, the outcome of contingencies, such as legal proceedings, plans related to share repurchases and dividends, government regulation and financial results. These statements are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties, many of which are beyond our control, and are based on assumptions that could prove to be inaccurate. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

- unanticipated safety, quality or efficacy concerns about our products;
- issues with any of our top products;
- failure of our R&D, acquisition and licensing efforts to generate new products and product lifecycle innovations;
- the possible impact and timing of competing products, including generic alternatives, on our products and our ability to compete against such products;

disruptive innovations and advances in medical practices and technologies;  
consolidation of our customers and distributors;

41 |

---

Table of Contents

changes in the distribution channel for companion animal products;  
failure to successfully acquire businesses, license rights or products, integrate businesses, form and manage alliances or divest businesses;  
restrictions and bans on the use of and consumer preferences regarding antibacterials in food-producing animals;  
perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products;  
adverse global economic conditions;  
increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;  
fluctuations in foreign exchange rates and potential currency controls;  
changes in tax laws and regulations;  
legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns, commercial disputes and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;  
failure to protect our intellectual property rights or to operate our business without infringing the intellectual property rights of others;  
product launch delays, inventory shortages, recalls or unanticipated costs caused by manufacturing problems and capacity imbalances;  
an outbreak of infectious disease carried by animals;  
adverse weather conditions and the availability of natural resources;  
the economic, political, legal and business environment of the foreign jurisdictions in which we do business;  
a cyber-attack, information security breach or other misappropriation of our data;  
quarterly fluctuations in demand and costs;  
governmental laws and regulations affecting domestic and foreign operations, including without limitation, tax obligations and changes affecting the tax treatment by the United States of income earned outside the United States that may result from pending and possible future proposals; and  
governmental laws and regulations affecting our interactions with veterinary healthcare providers.

However, there may also be other risks that we are unable to predict at this time. These risks or uncertainties may cause actual results to differ materially from those contemplated by a forward-looking statement. You should not put undue reliance on forward-looking statements. Forward-looking statements speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q and 8-K reports and our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the above to be a complete discussion of all potential risks or uncertainties.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

A significant portion of our revenue and costs are exposed to changes in foreign exchange rates. In addition, our outstanding borrowings may be subject to risk from changes in interest rates and foreign exchange rates. The overall objective of our financial risk management program is to seek to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using certain financial instruments. These practices may change as economic conditions change.

#### **Foreign exchange risk**

Our primary net foreign currency translation exposures are the Australian dollar, Brazilian real, Canadian dollar, Chinese renminbi, euro, and U.K. pound. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities.

Foreign exchange risk is also managed through the use of foreign currency forward-exchange contracts. These contracts are used to offset the potential earnings effects from mostly intercompany short-term foreign currency assets and liabilities that arise from operations.

Our financial instrument holdings at March 31, 2019, were analyzed to determine their sensitivity to foreign exchange rate changes. The fair values of these instruments were determined using Level 2 inputs. The sensitivity analysis of changes in the fair value of all foreign currency forward-exchange contracts at March 31, 2019, indicates that if the U.S. dollar were to appreciate against all other currencies by 10%, the fair value of these contracts would increase by \$13 million, and if the U.S. dollar were to weaken against all other currencies by 10%, the fair value of these contracts would decrease by \$17 million. For additional details, see Notes to Condensed Consolidated Financial Statements—*Note 9C. Financial Instruments: Derivative Financial Instruments*.

#### **Interest rate risk**

Our outstanding debt balances are predominantly fixed rate debt. While changes in interest rates will have no impact on the interest we pay on our fixed rate debt, interest on our \$300 million aggregate principal amount of 2018 Floating Rate Senior Notes due 2021, as well as interest on our commercial paper and revolving credit facility will be exposed to interest rate fluctuations. At March 31, 2019, there were no commercial paper borrowings outstanding and no outstanding principal balance under our revolving credit facility. See Notes to Condensed Consolidated Financial Statements—*Note 9C. Financial Instruments: Derivative Financial Instruments*.

### **Item 4. Controls and Procedures**

#### **Disclosure Controls and Procedures**

An evaluation was carried out under the supervision and with the participation of the company's management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation as of March 31, 2019, the company's Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures are effective at a reasonable level of assurance in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.

#### **Changes in Internal Control over Financial Reporting**

On July 31, 2018, the company completed the acquisition of Abaxis, Inc. (Abaxis). In our 2018 Annual Report on Form 10-K, we excluded Abaxis from our evaluation of internal control over financial reporting. Since the acquisition, Zoetis has extended its oversight and monitoring processes that support our internal control over financial reporting, as well as its disclosure controls and procedures, and we continue to integrate the acquired operations of Abaxis. Except for changes in internal control over financial reporting relating to the integration of Abaxis, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents**PART II — OTHER INFORMATION****Item 1. Legal Proceedings**

The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements—*Note 16. Commitments and Contingencies* in *Part I—Item 1*, of this Quarterly Report on Form 10-Q.

**Item 1A. Risk Factors**

In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in the "Our Operating Environment" and "Forward-Looking Statements and Factors That May Affect Future Results" sections of the MD&A and in Part I, Item 1A. "Risk Factors," of our 2018 Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results and which are incorporated by reference herein. Set forth below are updates to certain of the risk factors disclosed in our 2018 Annual Report on Form 10-K.

**Risks related to our business and industry*****An outbreak of infectious disease carried by animals could negatively affect the sale and production of our products.***

Sales of our livestock products could be materially adversely affected by the outbreak of disease carried by animals, which could lead to the widespread death or precautionary destruction of animals as well as the reduced consumption and demand for animal protein. In addition, outbreaks of disease carried by animals may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products due to reduced herd or flock sizes. In recent years, outbreaks of various diseases, including African Swine Fever, avian influenza, foot-and-mouth disease, bovine spongiform encephalopathy (otherwise known as BSE or mad cow disease) and porcine epidemic diarrhea virus (otherwise known as PEDv), have impacted the animal health business. For example, recent outbreaks of African Swine Fever have seriously impacted swine herds primarily in China and certain Southeast Asian countries, and as a result sales of our swine products there have been negatively impacted. The further spread of African Swine Fever within China, and its continued expansion to other countries, could further impact the size of swine herds globally and therefore the demand for our swine products, and if widespread, could have a material impact on our financial results. The discovery of additional cases of any of these, or new, diseases may result in additional restrictions on animal proteins, reduced herd sizes, or reduced demand for, animal protein, which may have a material adverse effect on our operating results and financial condition. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

The following table provides information with respect to the shares of the company's common stock repurchased during the quarter ended March 31, 2019:

	Issuer Purchases of Equity Securities			
	Total Number of Shares Purchased <sup>(a)</sup>	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
January 1 - January 31, 2019	648,212	\$84.46	647,368	\$2,246,468,733
February 1 - February 28, 2019	749,741	\$91.32	505,067	\$2,201,196,469
March 1 - March 31, 2019	523,623	\$96.22	520,127	\$2,150,907,880
	1,921,576	\$90.34	1,672,562	\$2,150,907,880

The company repurchased 249,014 shares during the three-month period ended March 31, 2019, that were not part of the publicly announced share repurchase<sup>(a)</sup> authorization. These shares were reacquired from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.

**Item 3. Defaults Upon Senior Securities**

None

**Item 4. Mine Safety Disclosures**

None

**Item 5. Other Information**

None

**Item 6. Exhibits**

<u>Exhibit 3.1</u>	Restated Certificate of Incorporation of the Registrant, effective as of May 13, 2014 (incorporated by reference to Exhibit 3.1 to Zoetis Inc.'s Quarterly Report on Form 10-Q filed on November 10, 2014 (File No. 001-35797))
<u>Exhibit 3.2</u>	By-laws of the Registrant, amended and restated as of February 19, 2016 (incorporated by reference to Exhibit 3.2 to Zoetis Inc.'s 2015 Annual Report on Form 10-K filed on February 24, 2016 (File No. 001-35797))
<u>Exhibit 15</u>	Accountants' Acknowledgment
<u>Exhibit 31.1</u>	Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302

## Edgar Filing: Zoetis Inc. - Form 10-Q

[Exhibit 31.2](#) Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302  
[Exhibit 32.1](#) Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906  
[Exhibit 32.2](#) Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906  
EX-101.INS XBRL INSTANCE DOCUMENT  
EX-101.SCH XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT  
EX-101.CAL XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT  
EX-101.LAB XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT  
EX-101.PRE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT  
EX-101.DEF XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

44 |

---

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Zoetis Inc.**

May 2, 2019 By: /S/ JUAN RAMÓN ALAIX

Juan Ramón Alaix

Chief Executive Officer and Director

May 2, 2019 By: /S/ GLENN DAVID

Glenn David

Executive Vice President and

Chief Financial Officer